Descriptor: "MESH : Survival Rate" - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"MESH : Survival Rate"' showing total 49 results

Start Over Descriptor "MESH : Survival Rate"

49 results on '"MESH : Survival Rate"'

1. Trends of incidence and survival in squamous-cell carcinoma of the anal canal in France: a population-based study

Author: Valérie Jooste, Zoé Uhry, Anne-Marie Bouvier, Jean Faivre, Sophie Grabar, N. Duport, Sylvain Manfredi, Aurélien Belot, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), FRANCIM, Réseau des registres français du cancer, Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Service de Biostatistiques [Lyon], Hospices Civils de Lyon (HCL), Service des Maladies de l'Appareil Digestif [CHU Rennes], CHU Pontchaillou [Rennes], Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National du Cancer (INCA), Santé publique France, Pontchaillou. Service des maladies de l'appareil digestif, Centre Hospitalier Universitaire [Rennes], Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Hospices Civils de Lyon ( HCL ), Centre Hospitalier Universitaire de Rennes, and Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: Male, Epidemiology, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Anus Neoplasms, MESH: Research Papers: Gastrointestinal Cancer, 0302 clinical medicine, MESH : Child, MESH: Child, Medicine, MESH: Incidence, MESH : Carcinoma, Squamous Cell, Child, education.field_of_study, MESH: Middle Aged, Obstetrics, MESH : Infant, MESH: Carcinoma, Squamous Cell, MESH: Follow-Up Studies, Anal canal, Anus Neoplasms, Prognosis, Research Papers, MESH: Infant, MESH : Incidence, 3. Good health, Survival Rate, Oncology, MESH: Young Adult, Child, Preschool, 030220 oncology & carcinogenesis, Carcinoma, Squamous Cell, 030211 gastroenterology & hepatology, medicine.medical_specialty, MESH : Research Papers: Gastrointestinal Cancer, Mitomycin, MESH : Young Adult, United-States, MESH: Prognosis, 03 medical and health sciences, MESH : Adolescent, Humans, Anal cancer, MESH : Middle Aged, MESH : Anus Neoplasms, education, Aged, Gynecology, MESH: Adolescent, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Public Health, Environmental and Occupational Health, Infant, MESH : Follow-Up Studies, MESH: Adult, Epidermoid Carcinoma, medicine.disease, Cervical-cancer, incidence, Randomized-trial, MESH: Female, Cancer Research, MESH: Registries, MESH : Child, Preschool, Risk Factors, MESH: Risk Factors, MESH : Female, Registries, Cervical cancer, MESH: Aged, MESH : Prognosis, Incidence (epidemiology), Smoking, MESH: Infant, Newborn, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, medicine.anatomical_structure, Female, France, Adult, Human-Papillomavirus, Risk, Adolescent, MESH: Survival Rate, anal cancer, MESH : Male, Population, Human Papilloma Virus Vaccine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Cancer Incidence, MESH : Infant, Newborn, survival, Young Adult, cancer registry, MESH : France, Survival rate, Radiotherapy, business.industry, Infant, Newborn, Cancer, MESH: Male, MESH: France, business, MESH : Registries, Follow-Up Studies
Abstract: IF 2.415; International audience; Data on anal cancer epidemiology are rare. The aim of this study was to report on trends of incidence and survival for anal cancer in France before the implementation of the human papilloma virus vaccine. This analysis was carried out on 1150 squamous-cell carcinomas of the anal canal diagnosed from 1989 to 2004 in a population of 5.7 million people covered by eight population-based cancer registries. Time trends in incidence were modeled using an age-period-cohort model. Net survival rates were obtained using the recently validated unbiased Pohar-Perme estimator. The incidence of squamous-cell carcinoma of the anal canal increased from 0.2 to 0.5/100 000 person-years among men and from 0.7 to 1.3/100 000 person-years among women from 1982 to 2012. Among women, the increase peaked after 2005, with an annual percentage change of +3.4% between 2005 and 2012, as compared with +2.6% among men. The net survival was 56% (95% confidence interval, 49-64) at 5 years and 48% (33-70) at 10 years among men. It was higher among women, at 65% (61-69) and 56% (50-63) at 5 and 10 years, respectively. The prognosis improved between 1989-1997 and 1998-2004. This improvement was slightly greater for men than for women, thus progressively reducing the gap between sexes. The incidence of squamous-cell anal canal cancer increased slightly among both sexes, but the increase was more marked among women than among men. The potential benefit of prophylactic female human papilloma virus vaccination against cervical cancer in France should be further evaluated.
Published: 2016

2. Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey. : Childbearing after HIPEC

Author: Andrea Hayes-Jordan, Paul H. Sugarbaker, Pablo Ortega-Deballon, Pompiliu Piso, Audrey Facy, Naoual Bakrin, Patrick Rat, Edward A. Levine, Olivier Glehen, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Département de chirurgie thoracique et digestive [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Baptist Medical Center, Wake Forest University, University Medical Center of Regensburg, Washington Cancer Institute, MD Anderson Cancer Center, and This work was supported by a grant from the University Hospital of Dijon and the Regional Council of Burgundy 2009.
Subjects: MESH : Mitomycin, MESH : Hyperthermia, Induced, MESH : Antineoplastic Combined Chemotherapy Protocols, Surgical oncology, Surveys and Questionnaires, Antineoplastic Combined Chemotherapy Protocols, MESH : Pregnancy Complications, Neoplastic, Medicine, MESH : Female, [ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery, Peritoneal Neoplasms, media_common, peritoneal carcinomatosis, MESH : Questionnaires, food and beverages, Intraperitoneal chemotherapy, MESH : Adult, MESH : Survival Rate, Combined Modality Therapy, Survival Rate, Treatment Outcome, Oncology, mesothelioma, Childbearing age, Female, Hyperthermic intraperitoneal chemotherapy, pregnancy, Cytoreductive surgery, Pregnancy Complications, Neoplastic, Adult, medicine.medical_specialty, Adolescent, Mitomycin, media_common.quotation_subject, MESH : International Agencies, MESH : Young Adult, Fertility, MESH : Treatment Outcome, pseudomyxoma, intraperitoneal chemotherapy, Article, MESH : Cisplatin, Young Adult, MESH : Peritoneal Neoplasms, MESH : Adolescent, Humans, HIPEC, business.industry, MESH : Humans, fungi, International survey, International Agencies, MESH : Follow-Up Studies, Hyperthermia, Induced, MESH : Chemotherapy, Cancer, Regional Perfusion, Surgery, childbearing, MESH : Pregnancy, Chemotherapy, Cancer, Regional Perfusion, Cisplatin, MESH : Combined Modality Therapy, business, Follow-Up Studies
Abstract: International audience; BACKGROUND: Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) can improve survival in selected patients with primary or secondary peritoneal malignancies. With the opportunity for long-term survival, questions about the impact of those procedures in fertility in women of childbearing age can be raised. MATERIALS AND METHODS: An international survey was performed among all teams participating in the International Peritoneal Surface Malignancy Group in order to collect data about pregnancies and their outcome in women having undergone previous CRS with adjuvant HIPEC. RESULTS: There were 7 pregnancies reported after CRS and HIPEC in women treated for peritoneal malignancies. All these women conceived spontaneously, most of them within 2 years after the procedure. They delivered most often by vaginal way after an uneventful pregnancy. Their newborns were healthy, except 1 case of congenital diaphragmatic hernia requiring emergent surgery. There were 2 additional uneventful pregnancies reported after the diagnosis of pseudomyxoma peritonei and before CRS and HIPEC, with the support of the medical team. Another woman having undergone oocytes retrieval and embryo cryopreservation prior to the surgery was mother of twins after the procedure via a surrogate mother. CONCLUSION: Childbearing after cytoreductive surgery and heated intraperitoneal chemotherapy is possible in women conserving their genital organs after the procedure. The question of fertility should be considered and discussed in women in reproductive age prior to cytoreductive surgery and heated intraperitoneal chemotherapy. Different options could be offered in this setting. Multidisciplinary decision making involving surgical oncologists and fertility specialists is important.
Published: 2011

3. Clinical similarities and differences of patients with X-linked lymphoproliferative syndrome type 1 (XLP-1/SAP deficiency) versus type 2 (XLP-2/XIAP deficiency)

Author: Pierre Bordigoni, Danielle Canioni, Michèle Milili, Nathalie Lambert, Claire Galambrun, Marie Ouachée-Chardin, Filomeen Haerynck, Françoise Le Deist, Despina Moshous, Christelle Lenoir, Stephanie Rigaud, Lionel Galicier, Fabien Touzot, Capucine Picard, Mohamed Hamidou, Hirokazu Kanegane, Ester Mejstrikova, Helen Chapel, Eduardo López-Granados, Stéphane Blanche, Alain Dabadie, Jana Pachlopnik Schmid, Pierre-Simon Rohrlich, Fabian Hauck, Geneviève de Saint Basile, Claudin Schiff, Jean-Louis Stephan, Alain Fischer, Isabelle Pellier, Nizar Mahlaoui, Sylvain Latour, Alain Fourmaintraux, Vincent Barlogis, IFR Necker-Enfants Malades (IRNEM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Developpement Normal et Pathologique du Système Immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service d'anatomie pathologique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Graduate School of Medicine, University of Toyama, Department of pediatrics, University of Oxford [Oxford], Teaching Hospital Motol and 2nd Medical School, Charles University, Department of Pediatric Hematology and Oncology, Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Service d'immuno-hématologie pédiatrique [CHU Necker], Service d'Hématologie pédiatrique, Hôpital de la Timone, Marseille, Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'hématologie pédiatrique, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Groupe Hospitalier Sud Réunion (GHSR), Centre Hospitalier Universitaire [Rennes], Centre de Référence Déficits Immunitaires Héréditaires (CEREDIH), Department of Paediatric Pulmonology, Ghent University Hospital, Service d'hématologie et immunologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Département de pédiatrie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, CHU Saint-Etienne, Centre d'Immunologie de Marseille - Luminy (CIML), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Génétique Humaine des Maladies Infectieuses (Inserm U980), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'étude des Déficits Immunitaires, Assistance Publique-Hôpitaux de Paris, Service d'Immunologie et d'Hématologie Pédiatrique, Chaire Médecine expérimentale (A. Fischer), Collège de France (CdF (institution)), University of Oxford, Centre Hospitalier Universitaire de Saint-Etienne [CHU Saint-Etienne] (CHU ST-E), Collège de France - Chaire Médecine expérimentale (A. Fischer), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Descartes - Paris 5 (UPD5), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), IFR Necker-Enfants Malades ( IRNEM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Groupe Hospitalier Sud Réunion ( GHSR ), Centre de Référence Déficits Immunitaires Héréditaires ( CEREDIH ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Centre d'Immunologie de Marseille - Luminy ( CIML ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Aix Marseille Université ( AMU ) -Centre National de la Recherche Scientifique ( CNRS ), Génétique Humaine des Maladies Infectieuses ( Inserm U980 ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris Descartes - Paris 5 ( UPD5 ), and Assistance publique - Hôpitaux de Paris (AP-HP)
Subjects: Male, MESH : Retrospective Studies, MESH: X-Linked Inhibitor of Apoptosis Protein, MESH : Aged, MESH : Child, Preschool, Biochemistry, Cohort Studies, Immunoenzyme Techniques, Hypogammaglobulinemia, MESH: Lymphoproliferative Disorders, 0302 clinical medicine, MESH : Child, MESH: Child, hemic and lymphatic diseases, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, XIAP Deficiency, Signaling Lymphocytic Activation Molecule Associated Protein, X-Linked Lymphoproliferative Syndrome, Child, MESH: Cohort Studies, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH : Lymphoproliferative Disorders, Intracellular Signaling Peptides and Proteins, MESH : Infant, Hematology, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH: Infant, 3. Good health, Survival Rate, MESH : Phenotype, Phenotype, MESH: Young Adult, Child, Preschool, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, MESH : Mutation, Adult, medicine.medical_specialty, MESH: Mutation, Adolescent, MESH: Survival Rate, MESH : Male, Immunology, MESH : Young Adult, MESH : Cohort Studies, X-Linked Inhibitor of Apoptosis Protein, Biology, MESH: Phenotype, Virus, Young Adult, 03 medical and health sciences, MESH : Intracellular Signaling Peptides and Proteins, MESH : Immunoenzyme Techniques, MESH : Adolescent, MESH: Intracellular Signaling Peptides and Proteins, medicine, Humans, MESH : Middle Aged, MESH: Immunoenzyme Techniques, Aged, Retrospective Studies, 030304 developmental biology, MESH: Adolescent, Hemophagocytic lymphohistiocytosis, Cytopenia, MESH: Humans, MESH : Humans, MESH: Child, Preschool, Infant, X-linked lymphoproliferative disease, MESH: Adult, MESH: Retrospective Studies, Cell Biology, medicine.disease, Lymphoproliferative Disorders, MESH: Male, MESH : X-Linked Inhibitor of Apoptosis Protein, Mutation, Histopathology, MESH: Female, 030215 immunology
Abstract: X-linked lymphoproliferative syndromes (XLP) are primary immunodeficiencies characterized by a particular vulnerability toward Epstein-Barr virus infection, frequently resulting in hemophagocytic lymphohistiocytosis (HLH). XLP type 1 (XLP-1) is caused by mutations in the gene SH2D1A (also named SAP), whereas mutations in the gene XIAP underlie XLP type 2 (XLP-2). Here, a comparison of the clinical phenotypes associated with XLP-1 and XLP-2 was performed in cohorts of 33 and 30 patients, respectively. HLH (XLP-1, 55%; XLP-2, 76%) and hypogammaglobulinemia (XLP-1, 67%; XLP-2, 33%) occurred in both groups. Epstein-Barr virus infection in XLP-1 and XLP-2 was the common trigger of HLH (XLP-1, 92%; XLP-2, 83%). Survival rates and mean ages at the first HLH episode did not differ for both groups, but HLH was more severe with lethal outcome in XLP-1 (XLP-1, 61%; XLP-2, 23%). Although only XLP-1 patients developed lymphomas (30%), XLP-2 patients (17%) had chronic hemorrhagic colitis as documented by histopathology. Recurrent splenomegaly often associated with cytopenia and fever was preferentially observed in XLP-2 (XLP-1, 7%; XLP-2, 87%) and probably represents minimal forms of HLH as documented by histopathology. This first phenotypic comparison of XLP subtypes should help to improve the diagnosis and the care of patients with XLP conditions.
Published: 2011

4. Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006

Author: Thibault Moreau, Yves Cottin, Guy-Victor Osseby, Christine Marie, Jérôme Durier, M. Giroud, Yannick Béjot, D. Ben Salem, G. Couvreur, Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Département de radiologie [Brest] (DR - Brest), Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] (CAPS), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] (IBMM), Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Montpellier (UM)-Ecole Nationale Supérieure de Chimie de Montpellier (ENSCM), Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Département de radiologie [Brest] ( DR - Brest ), Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), Cognition, Action, et Plasticité Sensorimotrice [Dijon - U1093] ( CAPS ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Institut des Biomolécules Max Mousseron [Pôle Chimie Balard] ( IBMM ), and Ecole Nationale Supérieure de Chimie de Montpellier ( ENSCM ) -Université de Montpellier ( UM ) -Centre National de la Recherche Scientifique ( CNRS )
Subjects: Male, MESH : Stroke, MESH: Registries, [SDV]Life Sciences [q-bio], MESH : Aged, MESH : Prospective Studies, 030204 cardiovascular system & hematology, Rate ratio, Brain Ischemia, MESH: Aged, 80 and over, 0302 clinical medicine, MESH: Risk Factors, Risk Factors, Atrial Fibrillation, MESH: Fibrinolytic Agents, MESH : Female, Prospective Studies, Registries, Myocardial infarction, Prospective cohort study, Stroke, MESH: Aged, Aged, 80 and over, education.field_of_study, MESH: Middle Aged, Cerebral infarction, Incidence (epidemiology), MESH: Brain Ischemia, Atrial fibrillation, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, 3. Good health, Survival Rate, MESH: Atrial Fibrillation, Cardiology, Female, France, Adult, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Population, MESH: Stroke, 03 medical and health sciences, Fibrinolytic Agents, Internal medicine, medicine, Humans, MESH : Middle Aged, cardiovascular diseases, MESH : Aged, 80 and over, MESH : France, education, Aged, MESH: Humans, [ SDV ] Life Sciences [q-bio], business.industry, MESH : Humans, MESH : Fibrinolytic Agents, MESH: Adult, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, MESH: France, MESH : Atrial Fibrillation, MESH : Brain Ischemia, Neurology (clinical), business, MESH: Female, MESH : Registries, 030217 neurology & neurosurgery
Abstract: Background: Atrial fibrillation (AF) is strongly associated with age, and epidemiologic studies are needed to evaluate the impact of both aging of the population and the use of anticoagulant therapy in patients with AF on the incidence of cardioembolic stroke with AF (CE/AF stroke). Methods: We evaluated trends in incidence rates, risk factors, prestroke therapy, and survival in CE/AF stroke from a prospective population-based registry, from 1985 to 2006. Results: A total of 3,064 ischemic strokes, including 572 (18.7%) CE/AF strokes, were recorded. Over the 22 years, a decrease in the incidence of overall CE/AF stroke was noted (incidence rate ratio 0.9858, 95% confidence interval [CI] 0.9731–0.9986; p = 0.03). We observed a higher prevalence of previous AF, previous myocardial infarction, and patients aged >70 years in CE/AF stroke ( p p = 0.003). A significant increase in the use of anticoagulants and antiplatelet agents was noted, and was particularly pronounced for CE/AF stroke with previous AF. For CE/AF stroke, survival rates were 72% at 1 month (95% CI 0.68–0.76), 52% at 1 year (95% CI 0.48–0.56), and 43% at 2 years (95% CI 0.39–0.48), and remained lower than those of other ischemic stroke. Conclusions: The decrease in the incidence of cardioembolic/atrial fibrillation stroke in our study was probably due to a slight increase in the utilization of antithrombotic therapy in patients with atrial fibrillation, but the use of such therapies will have to increase further because of the expected aging of the population in coming years. AF = atrial fibrillation; CE = cardioembolic; CI = confidence interval; IRR = incidence rate ratios.
Published: 2009

5. Chemotherapy at the End of Life: Factors of Prescription

Author: Julia Salleron, Vincent Massard, Béatrice Weber, Thierry Conroy, Ivan Krakowski, Institut de Cancérologie de Lorraine - Alexis Vautrin (ICL), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Institut de Cancérologie de Lorraine - Alexis Vautrin ( ICL ), Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Institut de Cancérologie de Lorraine - Alexis Vautrin [Nancy] (UNICANCER/ICL), and UNICANCER
Subjects: Male, MESH: Decision Making, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, medicine.medical_treatment, Decision Making, MESH : Terminal Care, Antineoplastic Agents, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, Humans, Medicine, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH : Palliative Care, Medical prescription, MESH : France, Intensive care medicine, General Nursing, ComputingMilieux_MISCELLANEOUS, Terminal Care, Chemotherapy, MESH: Humans, business.industry, Palliative Care, MESH : Humans, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, General Medicine, MESH : Survival Rate, MESH : Neoplasms, MESH : Decision Making, MESH: Male, Survival Rate, MESH: France, MESH : Antineoplastic Agents, MESH: Terminal Care, Anesthesiology and Pain Medicine, 030220 oncology & carcinogenesis, MESH: Antineoplastic Agents, Female, MESH: Palliative Care, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, France, business, MESH: Female
Abstract: International audience
Published: 2015

6. Relationships between sex, early valve surgery and mortality in patients with left-sided infective endocarditis analysed in a population-based cohort study

Author: Xavier Duval, François Alla, Christine Selton-Suty, Bruno Hoen, Laetitia Minary, Lucile Schubel, Thanh Doco-Lecompte, Catherine Chirouze, Elodie Curlier, Marie-Line Erpelding, CHU Pointe-à-Pitre/Abymes [Guadeloupe], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université Paris Descartes - Paris 5 (UPD5)-Université de Lorraine (UL), Centre d'Investigation Clinique - Epidemiologie Clinique/essais Cliniques Nancy, Cancéropôle du Grand Est-Institut National de la Santé et de la Recherche Médicale (INSERM), Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), INSERA CIC, Hôpital Bichat - Claude Bernard, Laboratoire Chrono-environnement - UFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Maladies chroniques, santé perçue, et processus d'adaptation ( APEMAC ), Université Paris Descartes - Paris 5 ( UPD5 ) -Université de Lorraine ( UL ), Cancéropôle du Grand Est-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Laboratoire Chrono-environnement - UFC (UMR 6249) ( LCE ), Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ) -Université Bourgogne Franche-Comté [COMUE] ( UBFC ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Maladies chroniques, santé perçue, et processus d'adaptation. Approches épidémiologiques et psychologiques. ( APEMAC - EA 4360 ), Université de Lorraine ( UL ) -Université Paris Descartes - Paris 5 ( UPD5 ), Laboratoire Chrono-environnement ( LCE ), and Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC )
Subjects: Male, Time Factors, MESH : Retrospective Studies, Heart Valve Diseases, Logistic regression, MESH: Risk Assessment, MESH: Proportional Hazards Models, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, Epidemiology, MESH : Population Surveillance, Medicine, MESH : Female, Hospital Mortality, MESH : Heart Valve Prosthesis Implantation, MESH : Endocarditis, Bacterial, MESH : Risk Assessment, MESH : Sex Distribution, Heart Valve Prosthesis Implantation, education.field_of_study, MESH : Prognosis, MESH: Middle Aged, MESH: Sex Distribution, MESH: Follow-Up Studies, Middle Aged, Prognosis, MESH : Survival Rate, MESH : Heart Valve Diseases, Survival Rate, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Aortic Valve, Population Surveillance, Infective endocarditis, MESH : Aortic Valve, Population study, Female, France, Cardiology and Cardiovascular Medicine, MESH : Time Factors, MESH: Heart Valve Prosthesis Implantation, medicine.medical_specialty, MESH: Survival Rate, MESH : Sex Factors, MESH : Male, Population, Risk Assessment, MESH: Prognosis, MESH: Population Surveillance, MESH : Hospital Mortality, Sex Factors, MESH: Sex Factors, Internal medicine, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, Humans, Endocarditis, MESH : Middle Aged, MESH: Endocarditis, Bacterial, MESH: Hospital Mortality, Sex Distribution, education, MESH : France, Proportional Hazards Models, Retrospective Studies, MESH: Humans, business.industry, Proportional hazards model, MESH : Humans, MESH: Time Factors, Retrospective cohort study, MESH : Follow-Up Studies, MESH: Retrospective Studies, Endocarditis, Bacterial, MESH: Heart Valve Diseases, medicine.disease, MESH : Proportional Hazards Models, MESH: Male, Surgery, MESH: France, business, MESH: Aortic Valve, MESH: Female, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Follow-Up Studies
Abstract: Objective Whether sex-related differences in the prognosis of infective endocarditis (IE) are due to differences in disease severity or comorbid patterns, physiological specificities or a treatment indication bias is unclear. We conducted an analysis of the pooled database of two population-based cohorts of IE to reassess the relationships between sex, early valve surgery (EVS) and outcome in patients with IE. Methods Demographic and baseline characteristics, complications and outcome were compared in men and women with Duke-definite left-sided IE. A propensity model for EVS was constructed using multivariate logistic regression. Factors associated with 1-year mortality were identified using multivariate Cox models adjusted for EVS factors. Results The study population included 466 (75%) men and 154 (25%) women. Compared with men, women were older (p=0.005), were more often on haemodialysis (p=0.04), more often had a mitral valve IE (50.0% vs 35.8%, p=0.02), less often developed a septic shock (p=0.05), less often underwent EVS (p=0.001) yet had comparable inhospital mortality rates (20.1% vs 20.0%, p=0.96) and similar 1-year survival probability (logrank p=0.68). Female sex was neither associated with EVS (OR 0.76 (95% CI 0.49 to 1.16)) nor mortality (HR 1.17 (95% CI 0.80 to 1.69)). However EVS was associated with an increased risk of death in women in the early postoperative period (HR 8.72 (95% CI 3.42 to 22.24), p= Conclusions Women underwent EVS less often than men. However female sex was independently associated with neither EVS nor 1-year mortality. The reasons for a higher risk of early postoperative mortality in women must still be elucidated.
Published: 2014

7. Wee1 inhibition potentiates Wip1-dependent p53-negative tumor cell death during chemotherapy

Author: Anastasia R. Goloudina, Elena Y. Kochetkova, Marc Bardou, Arlette Hammann, Oleg N. Demidov, Sarah Richaud, Carmen Garrido, Olga A. Fedorova, Nickolai A. Barlev, Burhan Uyanik, V Clausse, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Institute of Cytology of the Russian Academy of Science (St. Petersburg), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Fondation ARC, laboratoire d'excellence ARC, La Ligue Contre le Cancer CCIR-GE (14-15-00636 ), fondation scientifique russe, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), and UNICANCER
Subjects: Wip1, Apoptosis, Cell Cycle Proteins, Pharmacology, MESH: G2 Phase Cell Cycle Checkpoints, Histones, MESH : Phosphorylation, Mice, MESH : Cell Cycle Proteins, MESH: Animals, MESH: Tumor Suppressor Protein p53, MESH: Histones, Kinase, Tp53 mutations, MESH : Mice, Transgenic, 3. Good health, Protein Phosphatase 2C, Survival Rate, MESH : Antineoplastic Agents, H2ax phosphorylation, P53 activation, MESH: Protein Phosphatase 2C, RNA Interference, MESH : Colorectal Neoplasms, MESH : Carrier Proteins, Histone H2ax, MESH: Mitochondria, Immunology, Human fibroblasts, MESH: Carrier Proteins, Antineoplastic Agents, MESH: Protein-Tyrosine Kinases, MESH: Protein-Serine-Threonine Kinases, MESH : Cisplatin, 03 medical and health sciences, MESH: Cell Cycle Proteins, Genotoxic stress, MESH : Protein-Tyrosine Kinases, Humans, MESH : Histones, Anticancer Therapy, MESH: DNA Damage, Cisplatin, MESH: Humans, MESH: Phosphorylation, [ SDV.BC ] Life Sciences [q-bio]/Cellular Biology, MESH : Humans, MESH : Nuclear Proteins, 030104 developmental biology, Cancer cell, MESH: Antineoplastic Agents, Carrier Proteins, MESH: Nuclear Proteins, MESH : Apoptosis, Dna-damage response, 0301 basic medicine, Cancer Research, MESH: Caspase 3, MESH : Caspase 3, Phosphorylation, Cytotoxicity, MESH : DNA Damage, Sensitization, medicine.diagnostic_test, Caspase 3, Nuclear Proteins, Protein-Tyrosine Kinases, MESH : Survival Rate, Mitochondria, G2 Phase Cell Cycle Checkpoints, Wee1, medicine.anatomical_structure, MESH : Protein Phosphatase 2C, Original Article, MESH : Mitochondria, Colorectal Neoplasms, medicine.drug, MESH : Protein-Serine-Threonine Kinases, MESH: Cell Line, Tumor, MESH: Survival Rate, MESH: Mice, Transgenic, MESH: RNA Interference, Phosphatase, Mice, Transgenic, [SDV.BC]Life Sciences [q-bio]/Cellular Biology, Biology, Protein Serine-Threonine Kinases, Flow cytometry, Cellular and Molecular Neuroscience, Cell Line, Tumor, MESH : Mice, medicine, Animals, MESH: Mice, MESH : Cell Line, Tumor, MESH: Apoptosis, Cell Biology, MESH : Tumor Suppressor Protein p53, MESH: Cisplatin, Cancer research, biology.protein, MESH : Animals, MESH : G2 Phase Cell Cycle Checkpoints, MESH : RNA Interference, Tumor Suppressor Protein p53, MESH: Colorectal Neoplasms, DNA Damage
Abstract: Inactivation of p53 found in more than half of human cancers is often associated with increased tumor resistance to anti-cancer therapy. We have previously shown that overexpression of the phosphatase Wip1 in p53-negative tumors sensitizes them to chemotherapeutic agents, while protecting normal tissues from the side effects of anti-cancer treatment. In this study, we decided to search for kinases that prevent Wip1-mediated sensitization of cancer cells, thereby interfering with efficacy of genotoxic anti-cancer drugs. To this end, we performed a flow cytometry-based screening in order to identify kinases that regulated the levels of γH2AX, which were used as readout. Another criterion of the screen was increased sensitivity of p53-negative tumor cells to cisplatin (CDDP) in a Wip1-dependent manner. We have found that a treatment with a low dose (75 nM) of MK-1775, a recently described specific chemical inhibitor of Wee1, decreases CDDP-induced H2AX phosphorylation in p53-negative cells and enhances the Wip1-sensitization of p53-negative tumors. We were able to reduce CDDP effective concentration by 40% with a combination of Wip1 overexpression and Wee1 kinase inhibition. We have observed that Wee1 inhibition potentiates Wip1-dependent tumor sensitization effect by reducing levels of Hipk2 kinase, a negative regulator of Wip1 pathway. In addition, during CDDP treatment, the combination of Wee1 inhibition and Wip1 overexpression has a mild but significant protective effect in normal cells and tissues. Our results indicate that inhibition of the negative regulators of Wip1 pathway, Wee1 and Hipk2, in p53-negative tumors could potentiate efficiency of chemotherapeutic agents without concomitant increase of cytotoxicity in normal tissues. The development and clinical use of Wee1 and Hipk1 kinase chemical inhibitors might be a promising strategy to improve anti-cancer therapy.
Published: 2016

8. Emergency reversal of anticoagulation: the real use of prothrombin complex concentrates: a prospective multicenter two year French study from 2006 to 2008

Author: Desmettre , Thibaut, Dubart , Alain-Eric, Capellier , Gilles, Fanara , Benoit, Puyraveau , Marc, Kepka , Sabrina, Coquart , Jeremy, Sheppard , Frances, Tazarourte , Karim, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), INSERM Centre Innovation Technologique 808 (INSERM CIT 808), and Centre hospitalier Marc Jacquet (Melun)
Subjects: Male, Emergency Medical Services, MESH : Prevalence, [SDV]Life Sciences [q-bio], MESH : Aged, MESH: Comorbidity, Comorbidity, MESH: Drug Toxicity, MESH : Anticoagulants, Risk Factors, MESH: Risk Factors, Prevalence, MESH : Female, Longitudinal Studies, MESH: Longitudinal Studies, MESH: Treatment Outcome, MESH: Aged, MESH : Longitudinal Studies, MESH : Drug Toxicity, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, MESH : Survival Rate, MESH : Risk Factors, Blood Coagulation Factors, Survival Rate, Treatment Outcome, MESH: Thromboembolism, MESH: Survival Analysis, MESH : Comorbidity, MESH: Emergency Medical Services, Female, France, MESH: Hemorrhage, Drug-Related Side Effects and Adverse Reactions, MESH: Survival Rate, MESH : Male, Hemorrhage, MESH : Treatment Outcome, MESH: Anticoagulants, MESH : Hemorrhage, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Thromboembolism, Humans, MESH : Emergency Medical Services, MESH : France, MESH : Blood Coagulation Factors, MESH: Prevalence, Aged, MESH: Humans, [ SDV ] Life Sciences [q-bio], MESH : Humans, Anticoagulants, MESH: Blood Coagulation Factors, Survival Analysis, MESH: Male, MESH : Thromboembolism, MESH: France, bacteria, MESH : Survival Analysis, MESH: Female
Abstract: International audience; INTRODUCTION: Prothrombin complex concentrate (PCC) for reversal of vitamin K antagonist (VKA) is the main therapeutic option in cases of life-threatening bleeding. Clinical use of PCC is poorly documented. METHODS: We prospectively assessed PCC use in four French emergency departments during a two year period 2006-2008 before publication of French Guidelines. An appropriate treatment was defined when PCC was recommended, with a dose of PCC above or equal to 20 UI/kg, with vitamin K and with an assessment of international normalized ratio (INR) after PCC. Time of diagnosis and PCC administration were collected, as INR values, thromboembolic events within seven days, hospital mortality. RESULTS: 256 patients received PCC for reversal of OAT. PCC was mainly prescribed for major intracerebral (ICH) or gastrointestinal hemorrhage. An appropriate treatment was observed in 26% of patients. Intra-hospital mortality for major bleeding was 33% for ICH and 26% for non-ICH major bleeding. A PCC dose>20 UI/kg was able to reach an INR
Published: 2012

9. Reduced-intensity conditioning before allogeneic hematopoietic stem cell transplantation in patients over 60 years: a report from the SFGM-TC

Author: Sylvie François, Agnes Buzyn, Mauricette Michallet, Nicole Gratecos, Didier Blaise, François Guilhot, Richard Szydlo, Reza Tabrizi, Mohamad Mohty, Gérard Socié, Nathalie Contentin, Madalina Uzunov, Nathalie Fegueux, Jacques-Olivier Bay, Patrice Chevallier, Anne Huynh, Simona Lapusan, Jean-Yves Cahn, Ibrahim Yakoub-Agha, Sébastien Maury, Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie et oncologie médicale, Hôpital Lapeyronie-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Université de Montpellier (UM), Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC), Service Hématologie, Centre Hospitalier Universitaire de Nice (CHU Nice), TheREx, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications, Grenoble - UMR 5525 (TIMC-IMAG), VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP )-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF)-Hematology, Université Joseph Fourier - Grenoble 1 (UJF)-CHU Grenoble-CHU Grenoble, Service d'hématologie greffe [Saint-Louis], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), UAM Allogreffes de CSH, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Unité de transplantation médullaire et laboratoire d'oncologie moléculaire, Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER-UNICANCER, Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Université Montpellier 1 ( UM1 ) -Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -Hôpital Lapeyronie, Institut de Chimie des Milieux et Matériaux de Poitiers ( IC2MP ), Université de Poitiers-Centre National de la Recherche Scientifique ( CNRS ), CHU Nice, Techniques de l'Ingénierie Médicale et de la Complexité - Informatique, Mathématiques et Applications [Grenoble] ( TIMC-IMAG ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Université Joseph Fourier - Grenoble 1 ( UJF ) -Institut polytechnique de Grenoble - Grenoble Institute of Technology ( Grenoble INP ) -IMAG-Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ) -Hematology, Université Joseph Fourier - Grenoble 1 ( UJF ) -CHU Grenoble-CHU Grenoble, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Université Toulouse III - Paul Sabatier ( UPS ), CRLCC Jean Perrin, Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers, Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Université Joseph Fourier - Grenoble 1 (UJF)-Institut polytechnique de Grenoble - Grenoble Institute of Technology (Grenoble INP)-IMAG-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA)-Hematology, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes
Subjects: Male, MESH: Tissue Donors, Multivariate analysis, Transplantation Conditioning, MESH : Retrospective Studies, MESH : Transplantation Conditioning, medicine.medical_treatment, MESH : Aged, Hematopoietic stem cell transplantation, Disease, Allo-HSCT, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Medicine, MESH : Female, MESH : Tissue Donors, MESH: Transplantation Conditioning, MESH: Aged, MESH: Middle Aged, Age Factors, Hematopoietic Stem Cell Transplantation, Hematology, MESH: Follow-Up Studies, Middle Aged, SFGM-TC, MESH : Survival Rate, MESH : Risk Factors, Tissue Donors, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, Reduced Intensity Conditioning, Hematologic Neoplasms, MESH : Disease-Free Survival, Female, MESH : Hematologic Neoplasms, medicine.medical_specialty, MESH: Survival Rate, MESH : Transplantation, Homologous, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, Disease-Free Survival, 03 medical and health sciences, Age, MESH : Hematopoietic Stem Cell Transplantation, Internal medicine, MESH: Transplantation, Homologous, Humans, Transplantation, Homologous, MESH : Middle Aged, In patient, MESH: Hematopoietic Stem Cell Transplantation, Aged, Retrospective Studies, MESH: Age Factors, Transplantation, MESH: Humans, business.industry, MESH : Humans, RIC, Complete remission, MESH : Follow-Up Studies, MESH: Retrospective Studies, Confidence interval, MESH: Male, Surgery, Elderly patients, Relative risk, MESH: Disease-Free Survival, MESH : Age Factors, business, MESH: Female, 030215 immunology, Follow-Up Studies, MESH: Hematologic Neoplasms
Abstract: International audience; This retrospective multicenter report assessed the outcome of 600 patients with hematologic diseases older than 60 years who received reduced-intensity conditioning (RIC) allogeneic hematopoietic stem cell transplantation (allo-HSCT), with the specific aim to compare outcomes of patients between 60 and 65 years old (N = 493) with those older than 65 years (N = 107). Except for donor age, there were no significant differences between the groups regarding patients, diseases, and allo-HSCT characteristics. At time of RIC allo-HSCT, 276 patients (46%) were in complete remission. With a median follow-up of 22.8 and 23.7 months in the younger and the older groups, respectively, 2-year relapse, nonrelapse mortality, disease-free survival, and overall survival rates were similar in both groups (29.6% vs. 20.4%; 29.9% vs. 34.6%; 40.6% vs. 46.7%; 49.2% vs. 50.2%, respectively; P = NS for all comparisons). In a Cox multivariate analysis, after adjustment for disease and transplant factors, age per se was not an adverse factor for survival (relative risk = 1.08; 95% confidence interval, 0.81-1.44, P = .62). We conclude that in selected patients, RIC allo-HSCT could be offered to patients over 65 years old.
Published: 2012

10. Inappropriate drug use and mortality in community-dwelling elderly with impaired kidney function--the Three-City population-based study.: Inappropriate drug use in the elderly with impaired kidney function

Author: Gaëlle Breton, Claudine Berr, Christophe Tzourio, Catherine Helmer, Bénédicte Stengel, Vincent Launay-Vacher, Marc Froissart, Nicolas Janus, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de physiologie, explorations fonctionnelles et radioisotopes [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Neuroépidémiologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Pharmacie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Subjects: Male, MESH : Aged, MESH : Prospective Studies, MESH: Community Health Planning, Inappropriate Prescribing, 030204 cardiovascular system & hematology, Kidney, Kidney Function Tests, MESH: Drug Toxicity, Cohort Studies, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Medicine, MESH : Female, 030212 general & internal medicine, Longitudinal Studies, Prospective Studies, Prospective cohort study, MESH: Longitudinal Studies, MESH: Cohort Studies, MESH : Longitudinal Studies, MESH: Aged, education.field_of_study, MESH : Prognosis, MESH : Drug Toxicity, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Follow-Up Studies, Prognosis, MESH : Survival Rate, MESH : Risk Factors, MESH : Kidney, 3. Good health, Survival Rate, Nephrology, MESH: Kidney Failure, Chronic, MESH: Kidney Function Tests, Female, France, Cohort study, Glomerular Filtration Rate, medicine.medical_specialty, Drug-Related Side Effects and Adverse Reactions, MESH: Survival Rate, MESH : Male, Population, Renal function, MESH : Cohort Studies, MESH : Kidney Failure, Chronic, Community Health Planning, Article, MESH: Prognosis, 03 medical and health sciences, MESH: Inappropriate Prescribing, Internal medicine, Humans, Dosing, Intensive care medicine, education, MESH : France, Survival rate, Contraindication, Aged, Transplantation, MESH: Humans, business.industry, Proportional hazards model, MESH : Kidney Function Tests, MESH : Humans, MESH : Glomerular Filtration Rate, MESH : Follow-Up Studies, MESH: Kidney, MESH: Male, MESH: Prospective Studies, MESH: France, MESH: Glomerular Filtration Rate, Kidney Failure, Chronic, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH : Community Health Planning, MESH : Inappropriate Prescribing, MESH: Female, Follow-Up Studies
Abstract: International audience; BACKGROUND: Glomerular filtration rate (GFR) decline with age increases the risk of inappropriate dosing of drugs. We investigated the determinants and the mortality associated with the use of drugs that are contraindicated or require dose adjustment according to kidney function among the community-dwelling elderly. METHODS: The Three-City population-based study included 8701 participants ≥65 years from 1999 to 2001. Exposure to the risk of inappropriate drug dosage was defined as reported use of either a contraindicated drug or one requiring dose adjustment according to the individual baseline glomerular filtration rate estimated (eGFR) with the Modification of Diet in Renal disease study equation. Six-year mortality was analysed using Cox models adjusted for several sociodemographic, biologic and clinical risk factors. RESULTS: The overall percentage of exposure to the risk of inappropriate drug use was 13.3% (contraindication, 0.8%): it was 52.5% (4.5%) in those with an eGFR of 30-59 and 96% (48%) in those 10% of the population took drugs requiring renal dosing adjustments. Regular monitoring of eGFR may prevent excess mortality associated with inappropriate drug prescription in the elderly.
Published: 2011

11. Efficacy and safety of early cyclosporine conversion to sirolimus with continued MMF-four-year results of the Postconcept study

Author: Isabelle Etienne, Pierre-François Westeel, Thierry Frouget, Yvon Lebranchu, B. Hurault de Ligny, Jean-Philippe Rerolle, Etienne Thervet, Antoine Thierry, Sandrine Girardot-Seguin, Bruno Moulin, Olivier Toupance, Mathias Büchler, Service de néphrologie et immunologie clinique [CHRU Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau-Université de Tours (UT), Service de néphrologie - hémodialyse et transplantation rénale, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service de néphrologie adultes [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de Néphrologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service de dyalise et transplantation, Université de Picardie Jules Verne (UPJV)-CHU Amiens-Picardie, Service de Néphrologie-Dialyse-Transplantation rénale [CHU Caen], Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN), service de néphrologie et transplantation, CHU Strasbourg, Service de Néphrologie, Dialyse, Transplantations [CHU Limoges], CHU Limoges, Service de néphrologie [Rennes], Université de Rennes (UR)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Roche SAS, Centre Hospitalier Universitaire de Reims (CHU Reims), Marquet, Pierre, Service de néphrologie et immunologie clinique, Université de Tours-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Service de néphrologie, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Université de Tours, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Université de Tours-CHRU Tours, Université de Poitiers-Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Université de Picardie Jules Verne ( UPJV ) -CHU Amiens-Picardie, service de néphrologie et transplantation rénale, CHU Caen, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], and Centre Hospitalier Universitaire de Reims ( CHU Reims )
Subjects: Male, 030232 urology & nephrology, 030230 surgery, Kidney Function Tests, urologic and male genital diseases, MESH: Cyclosporine, MESH: Kidney Transplantation, 0302 clinical medicine, Chronic allograft nephropathy, Immunology and Allergy, Medicine, MESH : Female, Pharmacology (medical), MESH : Immunosuppressive Agents, MESH : Graft Survival, education.field_of_study, Proteinuria, MESH: Middle Aged, Graft Survival, Middle Aged, MESH : Adult, [SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciences, MESH : Survival Rate, 3. Good health, Survival Rate, [SDV.SP] Life Sciences [q-bio]/Pharmaceutical sciences, MESH: Kidney Failure, Chronic, MESH: Kidney Function Tests, Cyclosporine, Female, MESH: Immunosuppressive Agents, medicine.symptom, Immunosuppressive Agents, medicine.drug, Adult, medicine.medical_specialty, MESH: Survival Rate, MESH: Graft Survival, MESH : Male, Population, Urology, Renal function, MESH : Kidney Failure, Chronic, Nephrotoxicity, 03 medical and health sciences, MESH : Cyclosporine, Humans, MESH : Middle Aged, education, Sirolimus, Transplantation, MESH: Humans, business.industry, MESH : Sirolimus, MESH : Humans, MESH : Kidney Function Tests, MESH: Adult, medicine.disease, Kidney Transplantation, MESH: Male, Surgery, Calcineurin, [ SDV.SP ] Life Sciences [q-bio]/Pharmaceutical sciences, Kidney Failure, Chronic, MESH : Kidney Transplantation, MESH: Sirolimus, business, MESH: Female
Abstract: International audience; Calcineurin inhibitor (CNI) withdrawal has been used as a strategy to improve renal allograft function. We previously reported that conversion from cyclosporine A (CsA) to sirolimus (SRL) 3 months after transplantation significantly improved renal function at 1 year. In the Postconcept trial, 77 patients in the SRL group and 85 in the CsA group were followed for 48 months. Renal function (Cockcroft and Gault) was significantly better at month 48 (M48) in the SRL group both in the intent-to-treat population (ITT): 62.6 mL/min/1.73 m(2) versus 57.1 mL/min/1.73 m(2) (p = 0.013) and in the on-treatment population (OT): 67.5 mL/min/1.73 m(2) versus 57.4 mL/min/1.73 m(2) (p = 0.002). Two biopsy proven acute rejection episodes occurred after M12 in each group. Graft and patient survival were comparable (graft survival: 97.4 vs. 100%; patient survival: 97.4 vs. 97.6%, respectively). The incidence of new-onset diabetes was numerically increased in the SRL group (7 vs. 2). In OT, three cancers occurred in the SRL group versus nine in the CsA group and mean proteinuria was increased in the SRL group (0.42 ± 0.44 vs. 0.26 ± 0.37; p = 0.018). In summary, the renal benefits associated with conversion of CsA to SRL, at 3 months posttransplantation, in combination with MMF were maintained for 4 years posttransplantation.
Published: 2011

12. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population

Author: Laurent Salomon, Lionel Badet, Georges Karam, Jacques Tostain, Pierre Bigot, Nathalie Rioux-Leclercq, Sébastien Barbet, Jean-Etienne Terrier, Bernard Escudier, Michel Soulié, Hicham Elkentaoui, Abdel-Rahmène Azzouzi, Fabrice Dugardin, Yann Neuzillet, Jean-Christophe Bernhard, Jacques Hubert, Aurélien Descazeaux, Karim Fehri, Nicolas Brichart, Philippe Paparel, J.M. Boutin, Laurent Guy, Baptiste Tisserand, Arnaud Mejean, Ismaël Galliot, Marc-Olivier Timsit, Laurence Bastien, Jérôme Rigaud, Antoine Valeri, Jacques Petit, Laurent Zini, Benoit Barrou, Christian Pfister, Xavier Tillou, Franck Bruyère, Fabien Saint, Herve Lang, Jean-Jacques Patard, Marie-Dominique Azemar, Denis Chautard, Julien Branchereau, Hervé Wallerand, Pascal Rischmann, Laura Poissonnier, Charles Deruelle, Lucille Martin, Laurence Albiges, Jacques Irani, Arnauld Villers, Thierry Lebret, Hervé Baumert, François Kleinclauss, Nicolas Terrier, Jean-Alexandre Long, Pierre-Etienne Theveniaud, M. Gigante, Frédéric Staerman, Jean-Marie Ferriere, Romain Mathieu, Morgan Rouprêt, F. Sallusto, Benoit Feuillu, Service d'urologie, Hôpital Foch [Suresnes], CHU Amiens-Picardie, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Grenoble-Hôpital Michallon, Service d'urologie-andrologie, CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] ( UJM ) -Hôpital nord, Service d'urologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Hôpital Saint-Joseph, Département de médecine oncologique [Gustave Roussy], Institut Gustave Roussy ( IGR ), CHU Strasbourg, Service d'anatomie et cytologie pathologiques [Rennes], Université d'Angers ( UA ) -CHU Angers, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Institut Mondor de recherche biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Service d'urologie [Tours], Hôpital Bretonneau-CHRU Tours, Hôtel-Dieu, Service d'Urologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Service de Chirurgie urologique et andrologie [CHU Limoges], CHU Limoges, Service d'urologie et transplantation rénales [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Service d'urologie [Rouen], CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Université de Reims Champagne-Ardenne ( URCA ), Centre hospitalier universitaire de Poitiers ( CHU Poitiers ) -Hôpital La Milétrie, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -CHU Necker - Enfants Malades [AP-HP], Service d'Urologie - Transplantation Rénale - Andrologie, CHU Toulouse [Toulouse]-Hôpital de Rangueil, CHU Toulouse [Toulouse], CHU Clermont-Ferrand-Hôpital Gabriel Montpied, Université de Brest ( UBO ) -Centre Hospitalier Régional Universitaire de Brest ( CHRU Brest ), Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bicêtre, members of the Comité de Transplantation de l'Association Française d'Urologie, the Comité de Cancérologie de l'Association Française d'Urologie, Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] (UJM)-Hôpital nord, Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Institut Gustave Roussy (IGR), Université d'Angers (UA)-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Institut Mondor de recherche biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Bretonneau-Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital Huriez-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service d'urologie et transplantation rénales [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Université de Reims Champagne-Ardenne (URCA), Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Hôpital La Milétrie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Brest (UBO)-Centre Hospitalier Régional Universitaire de Brest (CHRU Brest), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Bicêtre-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Service d'anatomie et cytologie pathologiques [Rennes] = Anatomy and Cytopathology [Rennes], CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours)-Hôpital Bretonneau, Service d'Urologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, CHU Clermont-Ferrand-CHU Gabriel Montpied [Clermont-Ferrand], CHU Clermont-Ferrand, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, De Villemeur, Hervé, CHU Saint-Etienne-Université Jean Monnet - Saint-Étienne (UJM)-Hôpital nord, Département d'Urologie-Andrologie et Transplantation Rénale [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: Male, [ SDV.MHEP.UN ] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Chi-Square Distribution, Time Factors, MESH : Retrospective Studies, 030232 urology & nephrology, MESH : Aged, Kaplan-Meier Estimate, MESH: Risk Assessment, urologic and male genital diseases, Gastroenterology, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Proportional Hazards Models, MESH : Carcinoma, Renal Cell, 0302 clinical medicine, Renal cell carcinoma, MESH: Risk Factors, Risk Factors, MESH : Female, MESH : Neoplasm Staging, MESH : Risk Assessment, MESH: Treatment Outcome, MESH: Aged, education.field_of_study, Univariate analysis, MESH: Middle Aged, MESH: Carcinoma, Renal Cell, MESH: Neoplasm Staging, Middle Aged, MESH : Adult, MESH : Survival Rate, MESH : Risk Factors, Kidney Neoplasms, 3. Good health, Survival Rate, Treatment Outcome, MESH: Kidney Failure, Chronic, 030220 oncology & carcinogenesis, Female, France, MESH : Time Factors, Adult, medicine.medical_specialty, MESH: Survival Rate, Urology, MESH : Male, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Risk Assessment, MESH : Kidney Failure, Chronic, End stage renal disease, MESH : Kaplan-Meier Estimate, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Humans, MESH : Middle Aged, education, MESH : France, Survival rate, Carcinoma, Renal Cell, MESH: Kaplan-Meier Estimate, Aged, Neoplasm Staging, Proportional Hazards Models, Retrospective Studies, MESH: Humans, Chi-Square Distribution, MESH : Chi-Square Distribution, business.industry, MESH: Time Factors, MESH : Humans, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH : Proportional Hazards Models, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH: Male, MESH : Kidney Neoplasms, Surgery, Transplantation, MESH: France, Kidney Failure, Chronic, MESH: Kidney Neoplasms, business, Kidney cancer, MESH: Female, Kidney disease
Abstract: International audience; BACKGROUND: Patients with end-stage renal disease (ESRD) are at risk of developing renal tumours. OBJECTIVE: Compare clinical, pathologic, and outcome features of renal cell carcinomas (RCCs) in ESRD patients and in patients from the general population. DESIGN, SETTING, AND PARTICIPANTS: Twenty-four French university departments of urology participated in this retrospective study. INTERVENTION: All patients were treated according to current European Association of Urology guidelines. MEASUREMENTS: Age, sex, symptoms, tumour staging and grading, histologic subtype, and outcome were recorded in a unique database. Categoric and continuous variables were compared by using chi-square and student statistical analyses. Cancer-specific survival (CSS) was assessed by Kaplan-Meier and Cox methods. RESULTS AND LIMITATIONS: The study included 1250 RCC patients: 303 with ESRD and 947 from the general population. In the ESRD patients, age at diagnosis was younger (55 ± 12 yr vs 62 ± 12 yr); mean tumour size was smaller (3.7 ± 2.6 cm vs 7.3 ± 3.8 cm); asymptomatic (87% vs 44%), low-grade (68% vs 42%), and papillary tumours were more frequent (37% vs 7%); and poor performance status (PS; 24% vs 37%) and advanced T categories (≥ 3) were more rare (10% vs 42%). Consistently, nodal invasion (3% vs 12%) and distant metastases (2% vs 15%) occurred less frequently in ESRD patients. After a median follow-up of 33 mo (range: 1-299 mo), 13 ESRD patients (4.3%), and 261 general population patients (27.6%) had died from cancer. In univariate analysis, histologic subtype, symptoms at diagnosis, poor PS, advanced TNM stage, high Fuhrman grade, large tumour size, and non-ESRD diagnosis context were adverse predictors for survival. However, only PS, TNM stage, and Fuhrman grade remained independent CSS predictors in multivariate analysis. The limitation of this study is related to the retrospective design. CONCLUSIONS: RCC arising in native kidneys of ESRD patients seems to exhibit many favourable clinical, pathologic, and outcome features compared with those diagnosed in patients from the general population.
Published: 2011

13. Childbearing after hyperthermic intraperitoneal chemotherapy: results from an international survey

Author: Ortega-Deballon , Pablo, Glehen , Olivier, Levine , Edward, Piso , Pompiliu, Sugarbaker , Paul, Hayes-Jordan , Andrea, Facy , Audrey, Bakrin , Naoual, Rat , Patrick, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ), Département de chirurgie thoracique et digestive [CHU de Dijon], Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Baptist Medical Center, Wake Forest University, University Medical Center of Regensburg, Washington Cancer Institute, MD Anderson Cancer Center, and This work was supported by a grant from the University Hospital of Dijon and the Regional Council of Burgundy 2009.
Subjects: MESH : Mitomycin, MESH : Hyperthermia, Induced, MESH : Antineoplastic Combined Chemotherapy Protocols, MESH : International Agencies, MESH : Young Adult, MESH : Treatment Outcome, pseudomyxoma, intraperitoneal chemotherapy, MESH : Cisplatin, MESH : Peritoneal Neoplasms, MESH : Adolescent, MESH : Pregnancy Complications, Neoplastic, MESH : Female, [ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery, HIPEC, MESH : Humans, peritoneal carcinomatosis, MESH : Questionnaires, MESH : Follow-Up Studies, MESH : Chemotherapy, Cancer, Regional Perfusion, MESH : Adult, MESH : Survival Rate, childbearing, MESH : Pregnancy, mesothelioma, pregnancy, MESH : Combined Modality Therapy
Abstract: International audience; BACKGROUND: Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) can improve survival in selected patients with primary or secondary peritoneal malignancies. With the opportunity for long-term survival, questions about the impact of those procedures in fertility in women of childbearing age can be raised. MATERIALS AND METHODS: An international survey was performed among all teams participating in the International Peritoneal Surface Malignancy Group in order to collect data about pregnancies and their outcome in women having undergone previous CRS with adjuvant HIPEC. RESULTS: There were 7 pregnancies reported after CRS and HIPEC in women treated for peritoneal malignancies. All these women conceived spontaneously, most of them within 2 years after the procedure. They delivered most often by vaginal way after an uneventful pregnancy. Their newborns were healthy, except 1 case of congenital diaphragmatic hernia requiring emergent surgery. There were 2 additional uneventful pregnancies reported after the diagnosis of pseudomyxoma peritonei and before CRS and HIPEC, with the support of the medical team. Another woman having undergone oocytes retrieval and embryo cryopreservation prior to the surgery was mother of twins after the procedure via a surrogate mother. CONCLUSION: Childbearing after cytoreductive surgery and heated intraperitoneal chemotherapy is possible in women conserving their genital organs after the procedure. The question of fertility should be considered and discussed in women in reproductive age prior to cytoreductive surgery and heated intraperitoneal chemotherapy. Different options could be offered in this setting. Multidisciplinary decision making involving surgical oncologists and fertility specialists is important.
Published: 2011

14. Epidemiology and prognostic significance of chronic kidney disease in the elderly--the Three-City prospective cohort study

Author: Claudine Berr, Muriel Rainfray, Christophe Tzourio, Marc Froissart, Bénédicte Stengel, Catherine Helmer, Marie Metzger, Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Descartes - Paris 5 (UPD5), Service de médecine gériatrique, CHU Bordeaux [Bordeaux]-Groupe Hospitalier Sud-Hôpital Xavier Arnozan, Neuropsychiatrie : recherche épidémiologique et clinique (PSNREC), Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Neuroépidémiologie, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Epidémiologie et Biostatistique [Bordeaux], Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM), De Lauzon-Guillain, Blandine, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris Descartes - Paris 5 ( UPD5 ), Pathologies du système nerveux : recherche épidémiologique et clinique, Université Montpellier 1 ( UM1 ) -IFR76-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), and Université Bordeaux Segalen - Bordeaux 2-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: Male, MESH : Prevalence, MESH : Aged, MESH : Prospective Studies, nic kidney disease, 030204 cardiovascular system & hematology, urologic and male genital diseases, Gastroenterology, chemistry.chemical_compound, 0302 clinical medicine, Interquartile range, MESH: Risk Factors, Risk Factors, Prevalence, MESH : Cardiovascular Diseases, MESH : Female, Prospective Studies, Prospective cohort study, MESH: Aged, MESH : Prognosis, Proteinuria, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: Follow-Up Studies, MESH : Survival Rate, Prognosis, MESH : Risk Factors, female genital diseases and pregnancy complications, 3. Good health, Survival Rate, Nephrology, MESH: Kidney Failure, Chronic, Cardiovascular Diseases, Creatinine, Female, medicine.symptom, Glomerular Filtration Rate, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Renal function, MESH: Creatinine, MESH : Kidney Failure, Chronic, elderly, MESH: Prognosis, Article, 03 medical and health sciences, MESH: Proteinuria, Internal medicine, medicine, Humans, Survival rate, MESH: Prevalence, Aged, 030203 arthritis & rheumatology, Transplantation, anaemia, MESH : Proteinuria, MESH: Humans, business.industry, MESH : Humans, MESH : Creatinine, MESH : Glomerular Filtration Rate, MESH: Cardiovascular Diseases, MESH : Follow-Up Studies, medicine.disease, mortality, MESH: Prospective Studies, MESH: Male, MESH: Glomerular Filtration Rate, Endocrinology, chemistry, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, Kidney Failure, Chronic, Microalbuminuria, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, Kidney disease, Follow-Up Studies
Abstract: International audience; BACKGROUND: Little is known about normal kidney function level and the prognostic significance of low estimated glomerular filtration rate (eGFR) in the elderly. METHODS: We determined age and sex distribution of eGFR with both the Modification of Diet in Renal Disease (MDRD) study and the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equations in 8705 community-dwelling elderly aged ≥ 65 years and studied its relation to 6-year mortality. In a subsample of 1298 subjects examined at 4 years, we assessed annual eGFR decline and clinically relevant markers including microalbuminuria (3-30 mg/mmol creatinine) with diabetes, proteinuria ≥ 50 mg/mmol, haemoglobin
Published: 2011

15. Trends in case-fatality rates in hospitalized nontraumatic subarachnoid hemorrhage: results of a population-based study in Dijon, France, from 1985 to 2006

Author: Damien, Biotti, Agnès, Jacquin, Mahjouba, Boutarbouch, Olivier, Bousquet, Jérôme, Durier, Douraied, Ben Salem, Douraïeb Ben, Salem, Frederic, Ricolfi, Jacques, Beaurain, Guy-Victor, Osseby, Thibault, Moreau, Maurice, Giroud, Yannick, Béjot, Neurochirurgie, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Groupe d'Etude de la Thrombose de Bretagne Occidentale (GETBO), Université de Brest (UBO)-Institut Brestois Santé Agro Matière (IBSAM), Université de Brest (UBO)-Université de Brest (UBO), Service de neuroradiologie, imagerie des urgences [CHU de Dijon], Service de Neurologie générale, vasculaire et dégénérative (CHU de Dijon), Registre Dijonnais des Accidents Vasculaires Cérébraux (AVC) - Dijon Stroke Registry, UNICANCER-UNICANCER-Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université de Brest (UBO)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Brestois Santé Agro Matière (IBSAM), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Laboratoire Electronique, Informatique et Image ( Le2i ), Université de Bourgogne ( UB ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique ( CNRS ), Groupe d'Etude de la Thrombose de Bretagne Occidentale ( GETBO ), Université de Brest ( UBO ), and Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon )
Subjects: Male, Pediatrics, MESH : Stroke, MESH: Registries, [SDV]Life Sciences [q-bio], MESH : Mortality, MESH : Aged, MESH : Prospective Studies, MESH: Subarachnoid Hemorrhage, MESH: Hospitalization, 030204 cardiovascular system & hematology, Cohort Studies, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, Case fatality rate, Outcome Assessment, Health Care, MESH : Female, Prospective Studies, Registries, Stroke, MESH: Cohort Studies, MESH: Treatment Outcome, MESH: Aged, education.field_of_study, MESH: Middle Aged, medicine.diagnostic_test, Mortality rate, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, 3. Good health, Hospitalization, Survival Rate, Treatment Outcome, MESH : Hospitalization, Female, France, Cohort study, Adult, medicine.medical_specialty, Subarachnoid hemorrhage, MESH : Outcome Assessment (Health Care), MESH: Survival Rate, MESH : Male, Population, MESH : Cohort Studies, MESH : Treatment Outcome, MESH: Stroke, 03 medical and health sciences, medicine, Humans, MESH : Middle Aged, Mortality, MESH : France, education, Survival rate, MESH: Outcome Assessment (Health Care), Aged, MESH: Humans, [ SDV ] Life Sciences [q-bio], MESH: Mortality, business.industry, Lumbar puncture, MESH : Humans, MESH: Adult, Subarachnoid Hemorrhage, medicine.disease, MESH: Male, MESH: Prospective Studies, Surgery, MESH: France, MESH : Subarachnoid Hemorrhage, Neurology (clinical), business, MESH: Female, MESH : Registries, 030217 neurology & neurosurgery
Abstract: International audience; BACKGROUND: Subarachnoid hemorrhage accounts for 2% to 5% of all strokes and is associated with high morbidity and mortality rates. Reports in the literature show that case-fatality rates vary with time and according to geographical area. OBJECTIVE: The objective of the study was to evaluate the case-fatality rates in subarachnoid hemorrhage at 1 and 6 months and to determine trends in these rates over 22 years using a population-based registry. METHODS: The Dijon Stroke Registry has enabled us to perform a comprehensive analysis of subarachnoid hemorrhage diagnosed in a population of >150 000 inhabitants hospitalized between 1985 and 2006 in the Dijon University Hospital, which has both a neurosurgery unit and a neuroradiology unit. Diagnosis was based on clinical and neuroimaging features and, when necessary, on lumbar puncture. RESULTS: Case-fatality rates for hospitalized subarachnoid hemorrhages at 1 and 6 months were 15.59% (95% confidence interval [CI], 9.37-25.34) and 16.84% (95% CI, 10.33-26.78), respectively. From 1985 to 1995, case-fatality rates for SAH at 1 and 6 months were 17.1% (95% CI, 8.1-34.2) and 17.7% (95% CI, 9.6-31.3), whereas from 1996 to 2006, they were 20.2% (95% CI, 10.2-37.8) and 19.7% (95% CI, 11.1-33.6), respectively. CONCLUSION: Case-fatality rates for hospitalized subarachnoid hemorrhages in this population-based study remained stable over 22 years, suggesting that this stroke subtype is still a very severe disease despite early management. Most deaths occurred during the first 30 days. Further work is necessary to evaluate levels of prehospital case-fatality in our population-based registry.
Published: 2010

16. A new rat model of prenatal bowel obstruction: development and early assessment

Author: Frédérique Sauvat, Franck Sturtz, Laurent Fourcade, Nadine Cerf-Bensussan, Sabine Sarnacki, Yoanne Mousseau, Naziha Khen-Dunlop, Biomolécules Thérapies anti-tumorales (EA4021), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503), Service de chirurgie pédiatrique viscérale, orthopédique et plastique [CHU Limoges], CHU Limoges, CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Interactions de l'épithelium intestinal avec le système immunitaire, Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de Biochimie et Génétique Moléculaire [CHU Limoges], Biomolécules Thérapies anti-tumorales ( EA4021 ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ), and Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM )
Subjects: Pathology, MESH : Immunohistochemistry, medicine.medical_treatment, MESH: Random Allocation, [SDV.NEU.NB]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, [ SDV.MHEP.PED ] Life Sciences [q-bio]/Human health and pathology/Pediatrics, MESH : Intestinal Obstruction, Gastroenterology, Random Allocation, 0302 clinical medicine, MESH: Pregnancy, Pregnancy, Reference Values, Prenatal Diagnosis, Medicine, MESH : Female, MESH: Animals, [ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery, [ SDV.GEN.GH ] Life Sciences [q-bio]/Genetics/Human genetics, MESH : Rats, Mortality rate, Intestinal atresia, MESH: Reference Values, General Medicine, MESH : Survival Rate, Immunohistochemistry, 3. Good health, Bowel obstruction, Survival Rate, Fetal Diseases, MESH: Fetal Diseases, [ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], [ SDV.NEU.NB ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]/Neurobiology, 030220 oncology & carcinogenesis, Gestation, 030211 gastroenterology & hepatology, Female, [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], MESH : Sensitivity and Specificity, medicine.medical_specialty, MESH: Rats, MESH: Survival Rate, MESH: Probability, MESH : Probability, Rat model, [ SDV.BBM.BM ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, MESH : Rats, Wistar, MESH : Reference Values, Sensitivity and Specificity, MESH : Random Allocation, 03 medical and health sciences, Internal medicine, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Animals, Rats, Wistar, MESH: Prenatal Diagnosis, MESH : Prenatal Diagnosis, Probability, Fetus, [SDV.MHEP.PED]Life Sciences [q-bio]/Human health and pathology/Pediatrics, business.industry, Fetal surgery, MESH : Fetal Diseases, MESH: Immunohistochemistry, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, MESH: Rats, Wistar, medicine.disease, MESH : Disease Models, Animal, MESH: Sensitivity and Specificity, Rats, MESH : Pregnancy, Disease Models, Animal, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, [ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC], Atresia, Pediatrics, Perinatology and Child Health, Surgery, MESH : Animals, MESH: Disease Models, Animal, MESH: Intestinal Obstruction, business, MESH: Female, Intestinal Obstruction
Abstract: International audience; PURPOSE: Although intestinal motility disorders often complicate the postoperative surgical management of newborns with congenital intestinal atresia, their pathogenesis remains unclear. Animal models of prenatal intestinal obstruction have been mainly developed in the lamb and the chicken. Despite new insights brought by these models, they have one or more limitations, such as high fetal mortality rates, high costs, long gestation periods, and an insufficient number of fetuses per litter. Moreover, some species are phylogenetically distant from mammals. METHODS: We developed a reproducible model of prenatal intestinal obstruction in the rat to study the histologic changes induced by the obstruction. We report, the technical devices and the first assessment of this atresia model in a didactic way to allow other researchers to easily reproduce the model. RESULTS: Prenatal intestinal obstructions in this study fulfilled all the macroscopic and histologic criteria usually listed by other models of prenatal intestinal obstruction that have been developed in other species. Furthermore with our model, we obtained a high success rate at a low cost. CONCLUSIONS: We presented in this study a reproducible model of prenatal intestinal obstruction in the rat with the macroscopical and histologic features of prenatal intestinal obstruction.
Published: 2010

17. Data integration and exploration for the identification of molecular mechanisms in tumor-immune cells interaction

Author: Anne Berger, Franck Pagès, Jérôme Galon, Gabriela Bindea, Bernhard Mlecnik, Fátima Sánchez-Cabo, Pornpimol Charoentong, Zlatko Trajanoski, Australian Ministry for Science and Research, Australian Science Fund, Association pour la Recherche contre le Cancer (ARC), European Commission, Institute for Genomics and Bioinformatics, Graz University of Technology [Graz] (TU Graz), Centre de Recherche des Cordeliers (CRC (UMR_S 872)), Université Pierre et Marie Curie - Paris 6 (UPMC)-Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Genomics Unit, Spanish National Centre for Cardiovascular Research, Assistance publique - Hôpitaux de Paris, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Graz University of Technology [Graz] ( TU Graz ), Centre de Recherche des Cordeliers ( CRC (UMR_S 872) ), Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Georges Pompidou European Hospital, and BMC, Ed.
Subjects: Databases, Factual, computer.software_genre, Proteomics, MESH : Biometry, 0302 clinical medicine, Software Design, Neoplasms, MESH: Neoplasms, MESH: Biometry, Cancer immunology, 0303 health sciences, MESH : Software Design, MESH : Survival Rate, 3. Good health, Survival Rate, [ SDV.BBM.GTP ] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], 030220 oncology & carcinogenesis, [SDV.BBM.GTP] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Identification (biology), Biotechnology, Data integration, MESH: Computational Biology, Biometry, lcsh:QH426-470, MESH: Survival Rate, Process (engineering), lcsh:Biotechnology, Computational biology, Biology, MESH : Databases, Factual, Data type, 03 medical and health sciences, lcsh:TP248.13-248.65, [SDV.BBM.GTP]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Genomics [q-bio.GN], Genetics, Humans, Cluster analysis, 030304 developmental biology, Tumor microenvironment, MESH: Humans, Research, MESH : Humans, Computational Biology, MESH : Neoplasms, MESH: Databases, Factual, lcsh:Genetics, MESH: Software Design, computer, MESH : Computational Biology
Abstract: Cancer progression is a complex process involving host-tumor interactions by multiple molecular and cellular factors of the tumor microenvironment. Tumor cells that challenge immune activity may be vulnerable to immune destruction. To address this question we have directed major efforts towards data integration and developed and installed a database for cancer immunology with more than 1700 patients and associated clinical data and biomolecular data. Mining of the database revealed novel insights into the molecular mechanisms of tumor-immune cell interaction. In this paper we present the computational tools used to analyze integrated clinical and biomolecular data. Specifically, we describe a database for heterogeneous data types, the interfacing bioinformatics and statistical tools including clustering methods, survival analysis, as well as visualization methods. Additionally, we discuss generic issues relevant to the integration of clinical and biomolecular data, as well as recent developments in integrative data analyses including biomolecular network reconstruction and mathematical modeling. This work was supported by the Austrian Ministry for Science and Research, GEN-AU Project Bioinformatics Integration Network (BIN), Austrian Science Fund (SFB Project Lipotoxicity), INSERM, the National Cancer Institute (INCa), Association pour la Recherche sur le Cancer (ARC), the Cancéropole Ile de France, Ville de Paris, and by the European Commission (FP7, Geninca Consortium, grant number 202230). Sí
Published: 2010

18. Comparison of clinical presentations and outcomes between patients with TGFBR2 and FBN1 mutations in Marfan syndrome and related disorders

Author: David Attias, Philippe Gabriel Steg, Franck Iserin, Daniel Sidi, Mireille Claustres, Laurence Faivre, Marlène Rio, Marie-Ange Delrue, Philippe Ravaud, Catherine Boileau, Carine Roy, Christine Francannet, Henri Plauchu, Sylvie Odent, Christophe Béroud, Guillaume Jondeau, Martine Le Merrer, Chantal Stheneur, Gwenaëlle Collod-Béroud, Stanislas Lyonnet, Philippe Khau Van Kien, Annick Rossi, Laurence Cohen, Didier Lacombe, Delphine Detaint, Consultation Marfan, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Bichat, Service de cardiologie, Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Génétique et épigénétique des maladies métaboliques, neurosensorielles et du développement (Inserm U781), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de pédiatrie, urgences enfants [CHU Ambroise-Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré [AP-HP], Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département d'épidémiologie, biostatistique et recherche clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Laboratoire de génétique des maladies rares. Pathologie moleculaire, etudes fonctionnelles et banque de données génétiques (LGMR), Université Montpellier 1 (UM1)-IFR3, Université Montpellier 1 (UM1)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre de génétique - Centre de référence des maladies rares, anomalies du développement et syndromes malformatifs (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Service de génétique médicale, Université de Bordeaux (UB)-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Unité de Cardiologie Pédiatrique, Hôpital Privé Jacques Cartier [Massy], Unité de Génétique Médicale, Hôtel-Dieu-CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I (UdA), Service de cardiologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service de Génétique Médicale [CHU Necker], Service de Génétique Clinique, Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Sud, Service de Génétique, Hôpital de l'Hôtel Dieu [CHU-HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Service de génétique [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Hémostase, bio-ingénierie et remodelage cardiovasculaires (LBPC), Université Paris 13 (UP13)-Université Paris Diderot - Paris 7 (UPD7)-Institut Galilée-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service de biochimie, d'hormonologie et de génétique moléculaire [CHU Amrboise Paré], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 (UPD7), Service de pédiatrie, urgences enfants [Ambroise-Paré], Hôpital Ambroise Paré [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Université Paris Diderot - Paris 7 (UPD7)-Université Paris 13 (UP13)-Université Sorbonne Paris Cité (USPC)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Galilée, Service de biochimie, d'hormonologie et de génétique moléculaire [Amrboise Paré], Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Ambroise Paré [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bichat, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Ambroise Paré [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Recherche Magellan, Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon-Institut d'Administration des Entreprises (IAE) - Lyon, Service de Génétique Médicale [CHU Clermont-Ferrand], CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Institut de génétique humaine (IGH), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], CHU Necker - Enfants Malades [AP-HP], Unité de génétique médicale, hôpital Sud, Hôpital Bichat - Claude Bernard, Modèles et méthodes de l'évaluation thérapeutique des maladies chroniques (U738 / UMR_S738), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Bichat, Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Génétique et épigénétique des maladies métaboliques, neurosensorielles et du développement ( Inserm U781 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Service de pédiatrie, urgences enfants, Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Ambroise Paré, Université Paris Diderot - Paris 7 ( UPD7 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Laboratoire de génétique des maladies rares. Pathologie moleculaire, etudes fonctionnelles et banque de données génétiques, Université Montpellier 1 ( UM1 ) -IFR3-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Montpellier ( UM ), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Université de Bordeaux ( UB ) -CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Hôtel-Dieu-CHU Clermont-Ferrand-Université d'Auvergne - Clermont-Ferrand I ( UdA ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Sud, Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Hôtel Dieu, CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Hémostase, bio-ingénierie et remodelage cardiovasculaires ( LBPC ), Université Paris 13 ( UP13 ) -Université Paris Diderot - Paris 7 ( UPD7 ) -Université Sorbonne Paris Cité ( USPC ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Galilée, Service de biochimie, d'hormonologie et de génétique moléculaire, IFR3, Université Montpellier 1 (UM1)-Université Montpellier 1 (UM1)-Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Paris Diderot - Paris 7 (UPD7)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche Magellan, Institut d'Administration des Entreprises (IAE) - Lyon-Université Jean Moulin - Lyon 3 (UJML), Université de Lyon-Université de Lyon, Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Diderot - Paris 7 (UPD7), and COLLOD-BEROUD, Gwenaëlle
Subjects: Male, MESH : Receptors, Transforming Growth Factor beta, MESH : Mitral Valve Prolapse, Gene mutation, Gastroenterology, Marfan Syndrome, 0302 clinical medicine, MESH: Pregnancy, MESH : Child, Pregnancy, Mitral valve, MESH: Child, Medicine, MESH: Incidence, Child, MESH: Aneurysm, Dissecting, Aortic dissection, 0303 health sciences, Mitral Valve Prolapse, MESH: Middle Aged, Incidence, Prognosis, MESH: Case-Control Studies, MESH : Incidence, Aortic Aneurysm, 3. Good health, Survival Rate, MESH : Phenotype, MESH: Young Adult, Cardiology and Cardiovascular Medicine, musculoskeletal diseases, MESH : Case-Control Studies, medicine.medical_specialty, MESH : Young Adult, MESH : Cohort Studies, Fibrillins, MESH: Phenotype, Sudden death, MESH: Prognosis, MESH: Protein-Serine-Threonine Kinases, 03 medical and health sciences, MESH: Mitral Valve Prolapse, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH : Adolescent, Physiology (medical), Humans, MESH : Middle Aged, MESH : Aneurysm, Dissecting, MESH: Adolescent, [SDV.GEN]Life Sciences [q-bio]/Genetics, MESH: Humans, MESH : Humans, Receptor, Transforming Growth Factor-beta Type II, Case-control study, [SDV.BBM.BM]Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, MESH: Adult, medicine.disease, MESH: Aortic Aneurysm, MESH : Pregnancy, MESH : Mitral Valve Insufficiency, Case-Control Studies, Mutation, [ SDV.GEN ] Life Sciences [q-bio]/Genetics, Receptors, Transforming Growth Factor beta, MESH: Female, Marfan syndrome, MESH: Mitral Valve Insufficiency, Fibrillin-1, Kaplan-Meier Estimate, 030204 cardiovascular system & hematology, [SDV.BBM.BM] Life Sciences [q-bio]/Biochemistry, Molecular Biology/Molecular biology, Cohort Studies, MESH : Female, MESH: Kaplan-Meiers Estimate, MESH: Cohort Studies, MESH : Prognosis, Incidence (epidemiology), Microfilament Proteins, Mitral Valve Insufficiency, MESH : Adult, [ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, Middle Aged, MESH : Survival Rate, [SDV.MHEP.CSC] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, MESH : Aortic Aneurysm, Phenotype, medicine.anatomical_structure, Female, MESH: Receptors, Transforming Growth Factor beta, MESH : Mutation, MESH : Protein-Serine-Threonine Kinases, Adult, MESH: Mutation, MESH : Microfilament Proteins, Adolescent, MESH: Survival Rate, MESH : Male, [SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics, Protein Serine-Threonine Kinases, MESH: Marfan Syndrome, Young Adult, MESH: Microfilament Proteins, Internal medicine, Survival rate, 030304 developmental biology, MESH : Marfan Syndrome, business.industry, MESH : Kaplan-Meiers Estimate, MESH: Male, Surgery, Aortic Dissection, [SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human genetics, business
Abstract: Background— TGFBR2 mutations were recognized recently among patients with a Marfan-like phenotype. The associated clinical and prognostic spectra remain unclear. Methods and Results— Clinical features and outcomes of 71 patients with a TGFBR2 mutation (TGFBR2 group) were compared with 50 age- and sex-matched unaffected family members (control subjects) and 243 patients harboring FBN1 mutations (FBN1 group). Aortic dilatation was present in a similar proportion of patients in both the TGFBR2 and FBN1 groups (78% versus 79%, respectively) but was highly variable. The incidence and average age for thoracic aortic surgery (31% versus 27% and 35±16 versus 39±13 years, respectively) and aortic dissection (14% versus 10% and 38±12 versus 39±9 years) were also similar in the 2 groups. Mitral valve involvement (myxomatous, prolapse, mitral regurgitation) was less frequent in the TGFBR2 than in the FBN1 group (all P TGFBR2 mutations, versus 32% with FBN1 mutations ( P =0.002). The rate of death was greater in TGFBR2 families before diagnosis but similar once the disease had been recognized. Most pregnancies were uneventful (without death or aortic dissection) in both TGFBR2 and FBN1 families (38 of 39 versus 213 of 217; P =1). Seven patients (10%) with a TGFBR2 mutation fulfilled international criteria for Marfan syndrome, 3 of whom presented with features specific for Loeys-Dietz syndrome. Conclusions— Clinical outcomes appear similar between treated patients with TGFBR2 mutations and individuals with FBN1 mutations. Prognosis depends on clinical disease expression and treatment rather than simply the presence of a TGFBR2 gene mutation.
Published: 2009

19. Achievement of at least very good partial response is a simple and robust prognostic factor in patients with multiple myeloma treated with high-dose therapy: long-term analysis of the IFM 99-02 and 99-04 Trials

Author: Michel Attal, Nicolas Ketterer, Thierry Lamy, Cyrille Hulin, Hervé Avet-Loiseau, Laurent Voillat, Thierry Facon, Jean-Luc Harousseau, Gerald Marit, Laurent Garderet, Claire Mathiot, François Guilhot, Catherine Charbonnel, Chantal Doyen, Philippe Moreau, Mauricette Michallet, Frédéric Garban, Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'hématologie clinique, Hôpital Hôtel-Dieu [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre de Recherche en Cancérologie Nantes-Angers (CRCNA), Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Laennec-Centre National de la Recherche Scientifique (CNRS)-Faculté de Médecine d'Angers-Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire d'Hématologie [Purpan], Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], Thales Alenia Space [Cannes], Thales Alenia Space, Département de cancérologie et d'hématologie, CHU Grenoble-Hôpital Michallon, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Hôpital Claude Huriez [Lille], CHU Lille, Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service des maladies du sang, CHU Bordeaux [Bordeaux]-Hôpital Haut-Lévêque [CHU Bordeaux], CHU Bordeaux [Bordeaux]-Groupe Hospitalier Sud, Microenvironnement et cancer (MiCa), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC), Hématologie et oncologie pédiatrique, Thales Alenia Space [Toulouse] (TAS), THALES [France], Service Hématologie - IUCT-Oncopole [CHU Toulouse], Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle IUCT [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Centre de Recherche en Cancérologie / Nantes - Angers (CRCNA), Centre hospitalier universitaire de Nantes (CHU Nantes)-Faculté de Médecine d'Angers-Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)-Centre National de la Recherche Scientifique (CNRS)-Hôpital Laennec-Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôtel-Dieu de Nantes, Hôpital Claude Huriez, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre de Recherche en Cancérologie / Nantes - Angers ( CRCNA ), CHU Angers-Centre hospitalier universitaire de Nantes ( CHU Nantes ) -Hôtel-Dieu de Nantes-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Hôpital Laennec-Centre National de la Recherche Scientifique ( CNRS ) -Faculté de Médecine d'Angers, Université Toulouse III - Paul Sabatier ( UPS ), Thales Alenia Space ( TAS ), THALES, Institut Mondor de Recherche Biomédicale ( IMRB ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Microenvironnement et cancer ( MiCa ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), Institut de Chimie des Milieux et Matériaux de Poitiers ( IC2MP ), and Université de Poitiers-Centre National de la Recherche Scientifique ( CNRS )
Subjects: Oncology, Cancer Research, MESH: Combined Modality Therapy, MESH: Remission Induction, MESH : Antineoplastic Combined Chemotherapy Protocols, medicine.medical_treatment, MESH: Multiple Myeloma, Hematopoietic stem cell transplantation, Dexamethasone, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, Medicine, Multiple myeloma, MESH : Prognosis, MESH: Middle Aged, Remission Induction, Hematopoietic Stem Cell Transplantation, Middle Aged, MESH : Survival Rate, Prognosis, Combined Modality Therapy, MESH: Transplantation, Autologous, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, Vincristine, 030220 oncology & carcinogenesis, MESH: Dexamethasone, MESH : Disease-Free Survival, Multiple Myeloma, MESH : Dexamethasone, medicine.drug, MESH : Vincristine, medicine.medical_specialty, MESH : Transplantation, Autologous, MESH: Survival Rate, Context (language use), MESH: Vincristine, [SDV.CAN]Life Sciences [q-bio]/Cancer, Transplantation, Autologous, Disease-Free Survival, MESH: Prognosis, 03 medical and health sciences, MESH: Doxorubicin, MESH : Hematopoietic Stem Cell Transplantation, Internal medicine, MESH : Doxorubicin, Humans, MESH : Middle Aged, Survival rate, MESH: Hematopoietic Stem Cell Transplantation, Very Good Partial Response, MESH : Remission Induction, MESH: Humans, business.industry, MESH : Humans, medicine.disease, Surgery, Transplantation, Doxorubicin, MESH: Disease-Free Survival, MESH : Combined Modality Therapy, MESH : Multiple Myeloma, business, 030215 immunology
Abstract: Purpose The prognostic impact of complete response (CR) achievement in multiple myeloma (MM) has been shown mostly in the context of autologous stem-cell transplantation. Other levels of response have been defined because, even with high-dose therapy, CR is a relatively rare event. The purpose of this study was to analyze the prognostic impact of very good partial response (VGPR) in patients treated with high-dose therapy. Patients and Methods All patients were included in the Intergroupe Francophone du Myelome 99-02 and 99-04 trials and treated with vincristine, doxorubicin, and dexamethasone (VAD) induction therapy followed by double autologous stem-cell transplantation (ASCT). Best post-ASCT response assessment was available for 802 patients. Results With a median follow-up of 67 months, median event-free survival (EFS) and 5-year EFS were 42 months and 34%, respectively, for 405 patients who achieved at least VGPR after ASCT versus 32 months and 26% in 288 patients who achieved only partial remission (P = .005). Five-year overall survival (OS) was significantly superior in patients achieving at least VGPR (74% v 61% P = .0017). In multivariate analysis, achievement of less than VGPR was an independent factor predicting shorter EFS and OS. Response to VAD had no impact on EFS and OS. The impact of VGPR achievement on EFS and OS was significant in patients with International Staging System stages 2 to 3 and for patients with poor-risk cytogenetics t(4;14) or del(17p). Conclusion In the context of ASCT, achievement of at least VGPR is a simple prognostic factor that has importance in intermediate and high-risk MM and can be informative in more patients than CR.
Published: 2009

20. Partial versus radical nephrectomy in patients with adverse clinical or pathologic characteristics

Author: Pierre I. Karakiewicz, Jacques Tostain, Karim Bensalah, Herve Lang, Luca Cindolo, B. Albouy, Alexandre de la Taille, Jean Marie Ferriere, Nazareno Suardi, Vincenzo Ficarra, Umberto Capitanio, Jean-Christophe Bernhard, Maxime Crepel, Claudio Jeldres, Didier Jacqmin, Arnaud Mejean, Paul Perrotte, Jean Jacques Patard, Christian Pfister, Marc Colombel, Cancer Prognostics and Health Outcome Unit, Université de Montréal (UdeM), Service d'urologie [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Department of Oncological and Surgical Sciences, Universita degli Studi di Padova, G. Rummo Hospital, Service d'urologie [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Service d'urologie-andrologie, CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] (UJM)-Hôpital nord, Service d'urologie [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Service d'urologie [Centre Hospitalier Lyon Sud - HCL], Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service d'urologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Descartes - Paris 5 (UPD5)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Strasbourg, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Service d'urologie [Rennes] = Urology [Rennes], Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Università degli Studi di Padova = University of Padua (Unipd), De Villemeur, Hervé, Université de Montréal, Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), CHU Saint-Etienne-Université Jean Monnet [Saint-Étienne] ( UJM ) -Hôpital nord, CHU Rouen-Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), and Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Descartes - Paris 5 ( UPD5 ) -CHU Necker - Enfants Malades [AP-HP]
Subjects: [ SDV.MHEP.UN ] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, Nephrology, Male, [SDV.MHEP.CHI] Life Sciences [q-bio]/Human health and pathology/Surgery, medicine.medical_treatment, MESH : Aged, 030232 urology & nephrology, Nephrectomy, [SDV.MHEP.UN]Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Carcinoma, Renal Cell, 0302 clinical medicine, MESH: Aged, 80 and over, Risk Factors, MESH: Risk Factors, MESH : Female, [ SDV.MHEP.CHI ] Life Sciences [q-bio]/Human health and pathology/Surgery, Young adult, Stage (cooking), Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Carcinoma, Renal Cell, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, Kidney Neoplasms, 3. Good health, Survival Rate, MESH: Young Adult, 030220 oncology & carcinogenesis, Female, Adult, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Urology, MESH : Young Adult, [SDV.CAN]Life Sciences [q-bio]/Cancer, [SDV.MHEP.CHI]Life Sciences [q-bio]/Human health and pathology/Surgery, 03 medical and health sciences, Young Adult, [SDV.CAN] Life Sciences [q-bio]/Cancer, Internal medicine, medicine, Carcinoma, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, Carcinoma, Renal Cell, Aged, MESH: Humans, business.industry, MESH : Humans, MESH : Nephrectomy, Histology, MESH: Adult, medicine.disease, [SDV.MHEP.UN] Life Sciences [q-bio]/Human health and pathology/Urology and Nephrology, MESH : Kidney Neoplasms, MESH: Male, Surgery, MESH: Nephrectomy, T-stage, MESH: Kidney Neoplasms, business, MESH: Female
Abstract: International audience; OBJECTIVES: To assess cancer-specific survival of partial nephrectomy (PN) patients with >or= 7-cm lesions or unfavorable pathology (stage T3a or Fuhrman grades III-IV). MATERIAL AND METHODS: At 13 participation centers, 4072 partial or radical nephrectomies (RN) were performed for RCC between 1984 and 2001. Of all procedures, 925 (22.7%) were for tumors > 7 cm, 973 (23.9%) had Fuhrman grades III or IV, and 861 (21.1%) had stage pT3a. None had nodal or distant metastases. Matched (age, gender, tumor size, T stage, histologic subtype, and Fuhrman grade [FG]) survival analyses addressed the effect of nephrectomy type (partial vs radical) on cancer-specific mortality. RESULTS: Partial nephrectomy for tumors > 7 cm was associated with higher mortality than RN (HR = 5.3; P = .025). No significant cancer-specific survival differences were recorded after PN for FG III-IV (HR = 0.7, P = .5) or for pT3a lesions (HR = 2.5, P = .9). CONCLUSIONS: Partial nephrectomy may undermine cancer control in patients with tumors > 7 cm. Conversely, after PN, the same cancer control rates as after RN may be expected in patients with Fuhrman grades III-IV or with pT3a histology.
Published: 2009

21. Epidemiology, management, and risk factors for death of invasive Candida infections in critical care: a multicenter, prospective, observational study in France (2005-2006)

Author: Leroy , Olivier, Gangneux , Jean-Pierre, Montravers , Philippe, Mira , Jean-Paul, Gouin , François, Sollet , Jean-Pierre, Carlet , Jean, Reynes , Jacques, Rosenheim , Michel, Regnier , Bernard, Lortholary , Olivier, Renseigné , Non, Service de Réanimation Médicale et des Maladies Infectieuses, Centre Hospitalier Gustave Dron, Signalisation et Réponses aux Agents Infectieux et Chimiques ( SeRAIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140, Régulations des équilibres fonctionnels du foie normal et pathologique, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département anesthésie-réanimation chirurgicale, Assistance publique - Hôpitaux de Paris (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Physiopathologie de la Résorption Osseuse et Thérapie des Tumeurs Osseuses Primitives, Université de Nantes ( UN ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Centre hospitalier universitaire de Nantes ( CHU Nantes ), service de réanimation polyvalente, Centre Hospitalier Victor Dupuy, Réanimation Médico-Chirurgicale, Groupe Hospitalier Paris Saint-Joseph, Centre d'infectiologie Necker-Pasteur [CHU Necker], CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique ( CNRS ), Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Physiopathologie des Adaptations Nutritionnelles (PhAN), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Centre hospitalier universitaire de Nantes (CHU Nantes), Institut Pasteur [Paris]-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UR), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de la Recherche Agronomique (INRA)-Université de Nantes (UN), Groupe Hospitalier Paris Saint-Joseph (hpsj), Institut Pasteur [Paris] (IP)-CHU Necker - Enfants Malades [AP-HP], Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-IFR140, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-IFR140-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Descartes - Paris 5 (UPD5), Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Necker - Enfants Malades [AP-HP], and Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Rennes 1 (UR1)
Subjects: Male, critically ill, MESH : Aged, MESH : Prospective Studies, Critical Care and Intensive Care Medicine, 0302 clinical medicine, Case fatality rate, Hospital Mortality, Prospective Studies, MESH: Incidence, Fungemia, MESH: Treatment Outcome, Cause of death, Aged, 80 and over, Cross Infection, 0303 health sciences, MESH: Middle Aged, Incidence, Candidiasis, MESH: Follow-Up Studies, MESH : Incidence, 3. Good health, Survival Rate, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, MESH: Young Adult, MESH: Critical Illness, MESH : Intensive Care Units, MESH : Cross Infection, medicine.medical_specialty, MESH: Probability, Critical Illness, MESH : Young Adult, MESH : Cohort Studies, Statistics, Nonparametric, MESH : Hospital Mortality, 03 medical and health sciences, MESH: Critical Care, MESH: Fungemia, Intensive care, MESH : Adolescent, Humans, MESH : Middle Aged, MESH: Hospital Mortality, MESH : Aged, 80 and over, Mycosis, Aged, MESH: Adolescent, MESH: Humans, 030306 microbiology, MESH : Humans, MESH: Adult, MESH : Follow-Up Studies, MESH: Antifungal Agents, medicine.disease, chemistry, MESH: Female, Fluconazole, Antifungal Agents, MESH : Critical Illness, Cohort Studies, MESH: Cause of Death, chemistry.chemical_compound, MESH : Candidiasis, MESH: Aged, 80 and over, Risk Factors, MESH: Risk Factors, [ SDV.MP ] Life Sciences [q-bio]/Microbiology and Parasitology, Cause of Death, MESH : Female, 030212 general & internal medicine, MESH: Cohort Studies, MESH : Critical Care, Candida, intensive care, MESH: Aged, MESH: Statistics, Nonparametric, fungemia, Middle Aged, MESH : Adult, MESH : Survival Rate, MESH : Risk Factors, MESH: Candidiasis, Intensive Care Units, Treatment Outcome, Female, epidemiology, France, medicine.drug, Adult, Adolescent, Critical Care, MESH: Survival Rate, MESH : Male, MESH : Probability, MESH : Antifungal Agents, MESH : Treatment Outcome, Young Adult, Internal medicine, medicine, MESH : France, MESH : Statistics, Nonparametric, Probability, MESH : Cause of Death, Voriconazole, business.industry, MESH: Cross Infection, MESH: Male, MESH: Prospective Studies, Surgery, MESH: France, MESH : Fungemia, MESH: Intensive Care Units, Caspofungin, business, Follow-Up Studies
Abstract: International audience; OBJECTIVE: To describe the evolving epidemiology, management, and risk factors for death of invasive Candida infections in intensive care units (ICUs). DESIGN: Prospective, observational, national, multicenter study. SETTING: One hundred eighty ICUs in France. PATIENTS: Between October 2005 and May 2006, 300 adult patients with proven invasive Candida infection who received systemic antifungal therapy were included. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: One hundred seven patients (39.5%) with isolated candidemia, 87 (32.1%) with invasive candidiasis without documented candidemia, and 77 (28.4%) with invasive candidiasis and candidemia were eligible. In 37% of the cases, candidemia occurred within the first 5 days after ICU admission. C. albicans accounted for 57.0% of the isolates, followed by C. glabrata (16.7%), C. parapsilosis (7.5%), C. krusei (5.2%), and C. tropicalis (4.9%). In 17.1% of the isolates, the causative Candida was less susceptible or resistant to fluconazole. Fluconazole was the empirical treatment most commonly introduced (65.7%), followed by caspofungin (18.1%), voriconazole (5.5%), and amphotericin B (3.7%). After identification of the causative species and susceptibility testing results, treatment was modified in 86 patients (31.7%). The case fatality ratio in ICU was 45.9% and did not differ significantly according to the type of episode. Multivariate analysis showed that factors independently associated with death in ICU were type 1 diabetes mellitus (odds ratio [OR] 4.51; 95% confidence interval [CI] 1.72-11.79; p = 0.002), immunosuppression (OR 2.63; 95% CI 1.35-5.11; p = 0.0045), mechanical ventilation (OR 2.54; 95% CI 1.33-4.82; p = 0.0045), and body temperature >38.2 degrees C (reference, 36.5-38.2 degrees C; OR 0.36; 95% CI 0.17-0.77; p = 0.008). CONCLUSIONS: More than two thirds of patients with invasive candidiasis in ICU present with candidemia. Non-albicans Candida species reach almost half of the Candida isolates. Reduced susceptibility to fluconazole is observed in 17.1% of Candida isolates. Mortality of invasive candidiasis in ICU remains high.
Published: 2009

22. The abdominoperineal resection itself is associated with an adverse outcome: the European experience based on a pooled analysis of five European randomised clinical trials on rectal cancer

Author: Joakim Folkesson, Marcel den Dulk, Krzysztof Bujko, Claus Rödel, Cornelis J.H. van de Velde, Laurence Collette, Hein Putter, Jean-François Bosset, Lars Påhlman, Corrie A.M. Marijnen, Department of Medical Statistics, Leiden University Medical Center (LUMC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), and Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC )
Subjects: Male, Oncology, Cancer Research, Time Factors, Colorectal cancer, MESH : Risk, MESH: Lymphatic Metastasis, MESH : Abdomen, MESH : Aged, Kaplan-Meier Estimate, Perineum, MESH : Randomized Controlled Trials as Topic, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Proportional Hazards Models, MESH : Adenocarcinoma, 0302 clinical medicine, MESH: Rectum, Abdomen, Medicine, MESH : Female, MESH: Kaplan-Meiers Estimate, MESH : Rectal Neoplasms, Randomized Controlled Trials as Topic, MESH: Treatment Outcome, MESH: Aged, MESH: Middle Aged, MESH: Risk, MESH : Neoplasm Recurrence, Local, Abdominoperineal resection, Hazard ratio, MESH : Lymphatic Metastasis, MESH: Follow-Up Studies, Middle Aged, MESH : Survival Rate, 3. Good health, Europe, Survival Rate, Treatment Outcome, Lymphatic Metastasis, 030220 oncology & carcinogenesis, MESH : Rectum, Female, 030211 gastroenterology & hepatology, MESH: Neoplasm Recurrence, Local, MESH : Time Factors, Risk, medicine.medical_specialty, animal structures, MESH: Survival Rate, MESH : Male, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Adenocarcinoma, MESH : Perineum, MESH: Abdomen, 03 medical and health sciences, Internal medicine, Humans, MESH : Middle Aged, MESH: Patient Selection, MESH: Perineum, Survival rate, Aged, Proportional Hazards Models, MESH: Humans, Rectal Neoplasms, business.industry, Proportional hazards model, Patient Selection, MESH : Humans, MESH: Adenocarcinoma, MESH: Time Factors, Rectum, Cancer, MESH: Rectal Neoplasms, MESH : Follow-Up Studies, MESH : Kaplan-Meiers Estimate, MESH : Patient Selection, MESH : Proportional Hazards Models, medicine.disease, MESH: Male, Surgery, Clinical trial, MESH: Randomized Controlled Trials as Topic, Propensity score matching, MESH: Europe, Neoplasm Recurrence, Local, business, MESH: Female, Follow-Up Studies
Abstract: International audience; PURPOSE: The aim of this study is to identify factors associated with the decision to perform an abdominoperineal resection (APR) and to assess if these factors or the surgical procedure itself is associated with circumferential resection margin (CRM) involvement, local recurrence (LR), overall survival (OS) and cancer-specific survival (CSS). PATIENTS AND METHODS: The Swedish Rectal Cancer Trial (SRCT), TME trial, CAO/ARO/AIO-94 trial, EORTC 22921 trial and Polish Rectal Cancer Trial (PRCT) were pooled. A propensity score was calculated, which indicated the predicted probability of undergoing an APR given gender, age and distance, and used in the multivariate analyses. RESULTS: An APR procedure was associated with an increased risk of CRM involvement [odd ratio (OR) 2.52, p
Published: 2009

23. Long-term survival expectations of cancer patients in Europe in 2000-2002

Author: Brenner, Hermann, Francisci, Silvia, De Angelis, Roberta, Marcos-Gragera, Rafael, Verdecchia, Arduino, Gatta, Gemma, Allemani, Claudia, Ciccolallo, Laura, Coleman, Michel, Sant, Milena, Oberaigner, W., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hã©delin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadiã©, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Moliniã©, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Ciampichini, R., Ciccolallo, L., Gatta, G., Micheli, A., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellã¹, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., De Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Zanetti, R., Patriarca, S., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Zambon, P., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., De Angelis, R., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Siudowska, U., Mè©zyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Å½akelj, M., Mateos, A., Izarzugaza, I., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sã¡nchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, Ã. ., Talbã¤ck, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Van Der Heijden, Louis, Greenberg, D. C., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Evaluative Epidemiology Unit, Fondazione IRCCS, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Department of Preventive and Predictive Medicine, Unit of Etiological Epidemiology and Prevention, Istituto Nazionale per lo Studio e la Cura dei Tumori, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), German Cancer Research Center - Deutsches Krebsforschungszentrum [Heidelberg] (DKFZ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Gerontology, Male, Cancer Research, MESH: Registries, Survival, MESH : Life Expectancy, MESH : Age Distribution, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Neoplasms, 80 and over, Medicine, Cancer registries, MESH: Neoplasms, MESH : Female, 030212 general & internal medicine, Registries, Young adult, MESH: Aged, Aged, 80 and over, MESH: Middle Aged, Relative survival, MESH : Adult, Middle Aged, MESH : Survival Rate, Prognosis, 3. Good health, Europe, Survival Rate, Oncology, MESH: Young Adult, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Cohort, Period Analysis, Female, cancer survival - long term, MESH: Life Expectancy, Adult, MESH: Survival Rate, Period analysis, Adolescent, Age Distribution, Aged, Humans, Life Expectancy, Survival Analysis, Young Adult, MESH : Male, MESH : Europe, MESH : Young Adult, Socio-culturale, [SDV.CAN]Life Sciences [q-bio]/Cancer, 03 medical and health sciences, MESH : Adolescent, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, MESH: Age Distribution, Survival analysis, MESH: Adolescent, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, medicine.disease, MESH : Neoplasms, MESH: Male, Life expectancy, MESH: Europe, MESH : Survival Analysis, business, MESH: Female, MESH : Registries, Demography
Abstract: International audience; Period analysis has been shown to provide more up-to-date estimates of long-term cancer survival rates than traditional cohort-based analysis. Here, we provide detailed period estimates of 5- and 10-year relative survival by cancer site, country, sex and age for calendar years 2000-2002. In addition, pan-European estimates of 1-, 5- and 10-year relative survival are provided. Overall, survival estimates were mostly higher than previously available cohort estimates. For most cancer sites, survival in countries from Northern Europe, Central Europe and Southern Europe was substantially higher than in the United Kingdom and Ireland and in countries from Eastern Europe. Furthermore, relative survival was also better in female than in male patients and decreased with age for most cancer sites.
Published: 2009

24. Feasibility of chemoradiotherapy for oesophageal cancer in elderly patients aged >or=75 years: a prospective, single-arm phase II study

Author: Marc Puyraveau, Philippe Maingon, Gilles Créhange, Joëlle Buffet-Miny, Stéphanie Servagi-Vernat, Mariette Mercier, Jean François Bosset, Mathieu Bosset, Service de Radiothérapie [CHRU Besançon], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'hématologie [Hôpital Edouard Herriot - HCL], Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Service de radiothérapie, CHU Besan-Hôpita Jean Minjoz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), and Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL )
Subjects: Male, MESH: Combined Modality Therapy, Esophageal Neoplasms, MESH : Aged, MESH : Prospective Studies, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Adenocarcinoma, MESH: Aged, 80 and over, Pharmacology (medical), MESH : Neoplasm Staging, MESH : Female, Prospective Studies, MESH : Carcinoma, Squamous Cell, Prospective cohort study, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, education.field_of_study, Standard treatment, MESH: Carcinoma, Squamous Cell, MESH: Follow-Up Studies, MESH: Neoplasm Staging, MESH : Survival Rate, Combined Modality Therapy, Survival Rate, MESH : Antineoplastic Agents, Treatment Outcome, MESH: Esophageal Neoplasms, Carcinoma, Squamous Cell, MESH : Disease-Free Survival, Female, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Population, Antineoplastic Agents, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Adenocarcinoma, Disease-Free Survival, MESH : Cisplatin, medicine, Humans, education, MESH : Aged, 80 and over, Survival rate, Aged, Neoplasm Staging, MESH: Humans, Performance status, business.industry, MESH : Humans, MESH: Adenocarcinoma, MESH: Quality of Life, MESH : Follow-Up Studies, MESH : Quality of Life, MESH: Male, MESH: Prospective Studies, Surgery, Regimen, MESH: Cisplatin, Localized disease, MESH: Disease-Free Survival, Quality of Life, MESH: Antineoplastic Agents, MESH : Esophageal Neoplasms, Geriatrics and Gerontology, Cisplatin, business, MESH : Combined Modality Therapy, MESH: Female, Chemoradiotherapy, Follow-Up Studies
Abstract: Background: The number of elderly patients with oesophageal cancer is expected to increase with the aging of the population and the rapidly increasing incidence of adenocarcinoma. Surgical resection is standard treatment for patients with localized disease considered fit for operation. However, elderly patients with oesophageal cancer are rarely referred for surgery. Objective: The aim of this prospective, single-arm, phase II study was to evaluate the feasibility and efficacy (tumour response) of chemoradiotherapy in the treatment of elderly patients with localized oesophageal cancer. Secondary endpoints were progression-free survival (PFS) and quality of life (QOL). Methods: The main study inclusion criteria were: patients aged ≥75 years; oesophageal cancer disease stage II–III; Charlson co-morbidity index score ≤4; Eastern Cooperative Oncology Group (ECOG) performance status 0–2; and weight loss
Published: 2009

25. Impact of genotype on survival of children with T-cell acute lymphoblastic leukemia treated according to the French protocol FRALLE-93: the effect of TLX3/HOX11L2 gene expression on outcome

Author: André Baruchel, Yves Perel, Anne Hagemejier, Guy Leverger, Judith Landman-Parker, Paola Ballerini, Virginie Gandemer, François Sigaux, Gérard Michel, Claudine Schmitt, Vahid Asnafi, Jean Michel Cayuela, Sylvie Fasola, Marie Françoise Auclerc, Luc Douay, Thierry Leblanc, Myriam Labopin, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service d'hématologie pédiatrique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Laboratoire d'hématologie, Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], CEREST-TC [CHU Saint-Antoine], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'onco-hématologie pédiatrique, hôpital Sud, Service d'hématologie pédiatrique et oncologie, CHU Bordeaux [Bordeaux]-Hôpital Pellegrin, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille (APHM)- Hôpital de la Timone [CHU - APHM] (TIMONE), Service d'hématologie, Service d'oncologie et hématologie, Hôpital d'enfants, Department of Human Genetics, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), supported by Chugai France (Dr. Thierry Guillot) and SFCE (Société Française des Cancers de l'Enfant)., Service d'hématologie-immunologie-oncologie pédiatrique, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris]-Université Paris Diderot - Paris 7 ( UPD7 ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], CHU Saint-Antoine [APHP]-Assistance publique - Hôpitaux de Paris (AP-HP)-Université Pierre et Marie Curie - Paris 6 ( UPMC ), Hôpital Sud, Université de la Méditerranée - Aix-Marseille 2-Assistance Publique - Hôpitaux de Marseille ( APHM ) - Hôpital de la Timone [CHU - APHM] ( TIMONE ), Catholic University of Leuven ( KU Leuven ), Service d'hématologie-immunologie-oncologie pédiatrique [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Université Pierre et Marie Curie - Paris 6 (UPMC), and De Villemeur, Hervé
Subjects: [SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Oncology, Time Factors, Transcription, Genetic, MESH : Genotype, MESH : Child, Preschool, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Genotype, 0302 clinical medicine, MESH : Child, hemic and lymphatic diseases, MESH: Child, Gene expression, Genotype, MESH : Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia-Lymphoma, Adult T-Cell, [ SDV.MHEP.HEM ] Life Sciences [q-bio]/Human health and pathology/Hematology, Medicine, MESH : Female, MESH : Homeodomain Proteins, MESH: Leukemia-Lymphoma, Adult T-Cell, Child, Regulation of gene expression, 0303 health sciences, MESH : Prognosis, Hematology, Hazard ratio, MESH : Infant, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, MESH: Follow-Up Studies, MESH: Gene Expression Regulation, Neoplastic, Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH : Adult, Prognosis, MESH : Survival Rate, MESH: Infant, 3. Good health, Gene Expression Regulation, Neoplastic, Survival Rate, NUP214-ABL1, Child, Preschool, 030220 oncology & carcinogenesis, outcome, Female, France, TLX3/HOX11L2, MESH : Time Factors, Adult, medicine.medical_specialty, Adolescent, MESH: Survival Rate, MESH : Gene Expression Regulation, Neoplastic, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, 03 medical and health sciences, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH : Adolescent, Internal medicine, MESH: Homeodomain Proteins, Humans, MESH : France, Survival rate, 030304 developmental biology, Homeodomain Proteins, MESH: Adolescent, MESH: Precursor Cell Lymphoblastic Leukemia-Lymphoma, MESH: Humans, business.industry, MESH: Transcription, Genetic, MESH : Humans, MESH: Time Factors, MESH: Child, Preschool, Infant, MESH : Transcription, Genetic, childhood T-cell acute lymphoblastic leukemia, MESH : Follow-Up Studies, MESH: Adult, MESH : Leukemia-Lymphoma, Adult T-Cell, MESH: Male, MESH: France, El Niño, Fusion transcript, Immunology, SIL-TAL1, business, MESH: Female, Follow-Up Studies
Abstract: International audience; BACKGROUND: The prognostic value of the ectopic activation of TLX3 gene expression, a major oncogenetic event associated with pediatric T-cell acute lymphoblastic leukemia, is controversial. Likewise, the frequency and the prognostic significance in pediatric T-cell acute lymphoblastic leukemia of the newly characterized NUP214-ABL1 fusion transcript is not yet clear. DESIGN AND METHODS: Two hundred children with T-cell acute lymphoblastic leukemia were treated in the French FRALLE-93 study from 1993 to 1999. The expression of TLX3, TLX1 and SILTAL1 genes was analyzed in samples from 92 patients by real-time quantitative reverse transcriptase polymerase chain reaction. Most of these samples were further studied for NUP214-ABL1 and CALM-AF10 fusion transcripts. RESULTS: The median follow-up was 7.9 years. At 5 years the overall survival (+/- standard deviation, %) was 62 (+/-3%) and leukemia-free survival was 58 (+/-3%). Patients with T-cell acute lymphoblastic leukemia positive for TLX3 had a poorer survival compared to those with T-ALL negative for TLX3 (overall survival: 45+/-11% vs. 57+/-5%, p=0.049). In multivariate analysis, TLX3 expression was an independent adverse risk factor predicting relapse with a hazard ratio of 2.44 (p=0.017) and an overall survival with a hazard ratio of 3.7 (p=0.001). NUP214-ABL1 was expressed in 16.6% of patients with TLX3-positive T-ALL (3 of 18); all of the patients with this association died before completion of the treatment. SILTAL expression did not significantly affect the prognosis of patients with T-cell acute lymphoblastic leukemia. Only three of 92 patients expressed the TLX1 gene and all three are alive. CONCLUSIONS: TLX3 gene expression is an independent risk factor predicting poor survival in childhood T-cell acute lymphoblastic leukemia. When co-expressed with TLX3, NUP214-ABL1 transcripts may increase the risk of poor survival.
Published: 2008

26. [Radiochemotherapy for oesophageal cancer: a locoregional failure history]

Author: Créhange, G., Maingon, P., Bosset, Jean-François, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: MESH: Combined Modality Therapy, Esophageal Neoplasms, MESH: Survival Rate, MESH: Treatment Failure, MESH : Survivors, [SDV.CAN]Life Sciences [q-bio]/Cancer, Adenocarcinoma, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH : Adenocarcinoma, MESH : Treatment Failure, Image Processing, Computer-Assisted, Humans, Survivors, Treatment Failure, MESH : Carcinoma, Squamous Cell, MESH: Radiotherapy Dosage, MESH: Survivors, MESH: Humans, MESH : Radiotherapy Dosage, MESH: Adenocarcinoma, MESH : Humans, Radiotherapy Dosage, MESH: Carcinoma, Squamous Cell, MESH : Survival Rate, Combined Modality Therapy, MESH: Image Processing, Computer-Assisted, Survival Rate, MESH: Esophageal Neoplasms, Carcinoma, Squamous Cell, MESH : Esophageal Neoplasms, MESH : Combined Modality Therapy, MESH : Image Processing, Computer-Assisted
Abstract: International audience; Esophageal cancer is characterized by various degrees of lymph node invasion and metastasis, both of which are associated with a poor prognosis. Exclusive concomitant radiochemotherapy (RCT) at a dose of 50 Gy delivered over 25 sessions, according to the RTOG 85-01 protocol, has led to improved five-year survival in 25% of patients, whereas no patients survive for five years using radiotherapy alone. Surgery, even when combined with preoperative RCT, also gives disappointing results for locally advanced tumors, which casts serious doubts on the usefulness of preoperative radiotherapy. By varying the fractionation schedule, the length of treatment or the radiotherapy volumes, it has become possible to obtain levels of locoregional relapse of around 35 to 45%. The increasing incidence of adenocarcinoma, which differs from epidermoid cancer with regard to the degree of lymph node invasion, has revived discussion on radiotherapy volumes. Given this difference between these two histological forms, we propose here a number of recommendations concerning radiotherapy volumes for patients presenting with cancer of the esophagus. Finally, analysis of the results for locoregional relapse according to the dose of radiation and the recommended radiotherapy volumes, has led us to investigate why increasing the dose of radiation has no impact in esophageal cancers.
Published: 2008

27. Primary cutaneous lymphomas: a population-based descriptive study of 71 consecutive cases diagnosed between 1980 and 2003

Author: Philippe Humbert, Marie Odile Riou-Gotta, Arlette Danzon, Isabelle Mermet, Fabien Pelletier, Evelyne Fournier, François Aubin, Département de dermatologie, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Hôpital Saint-Jacques-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Registre des tumeurs du Doubs et du Territoire de Belfort [CHRU Besançon], Pôle cancérologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Saas, Philippe, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques-Université de Franche-Comté ( UFC ), Registre des Tumeurs du Doubs, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -EA2276-Réseau FRANCIM, Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques-Université de Franche-Comté (UFC), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO)
Subjects: Male, Cancer Research, Skin Neoplasms, MESH : Time, CBCL, 030207 dermatology & venereal diseases, MESH : Lymphoma, B-Cell, 0302 clinical medicine, hemic and lymphatic diseases, Epidemiology, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH : Female, MESH: Incidence, MESH : Lymphoma, T-Cell, Cutaneous, MESH : Mycosis Fungoides, education.field_of_study, MESH: Middle Aged, MESH: Time, Incidence (epidemiology), Incidence, Hematology, Middle Aged, MESH : Survival Rate, MESH : Incidence, MESH: Lymphoma, T-Cell, Cutaneous, 3. Good health, Lymphoma, T-Cell, Cutaneous, Survival Rate, Oncology, 030220 oncology & carcinogenesis, MESH: Sezary Syndrome, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, medicine.medical_specialty, Lymphoma, B-Cell, MESH: Survival Rate, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH : Male, Population, Time, 03 medical and health sciences, Mycosis Fungoides, medicine, Humans, Sezary Syndrome, MESH : Middle Aged, MESH : France, education, MESH: Lymphoma, B-Cell, MESH : Sezary Syndrome, Mycosis fungoides, MESH: Humans, business.industry, MESH: Mycosis Fungoides, MESH: Skin Neoplasms, MESH : Skin Neoplasms, MESH : Humans, Cancer, medicine.disease, Dermatology, MESH: Male, Lymphoma, Surgery, Cancer registry, MESH: France, business, MESH: Female
Abstract: International audience; Although primary cutaneous lymphomas (PCL) are the second most common group of extra-nodal non-Hodgkin lymphomas, few epidemiological data are available in the literature, and most of them are provided by large databases from population-based cancer registries in the US or patients attending a single institution. We conducted this study to investigate the epidemiological and clinical features of PCL diagnosed in the department of Doubs from 1980 to 2003. Data were collected from the Doubs cancer registry from 1980 to 2003. Seventy-one patients with PCL were investigated. 82% were cutaneous T-cell lymphoma (CTCL) and 18% were cutaneous B-cell lymphoma (CBCL). Among CTCL, mycosis fungoides (MF) represented 58% and Sezary syndrome 10%. The standardised incidence rate of PCL was 0.42 for 100 000 person-years and significantly increased from 0.21 in 1980-1984 to 0.70 in 2000-2003 (p
Published: 2008

28. Using PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)

Author: Studer , Urs E, Collette , Laurence, Whelan , Peter, Albrecht , Walter, Casselman , Jacques, De Reijke , Theo, Knönagel , Hartmut, Loidl , Wolfgang, Isorna , Santiago, Sundaram , Subramanian K, Debois , Muriel, Renseigné , Non, Bittard , Hugues, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Service de Néphrologie et Urologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Service d'urologie, andrologie et transplantation rénale, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, CCA -Cancer Center Amsterdam, Urology, and 06 Operations Centre and intensive care
Subjects: Male, Nephrology, MESH: Orchiectomy, Time Factors, 030232 urology & nephrology, MESH : Aged, urologic and male genital diseases, law.invention, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Prostate cancer, 0302 clinical medicine, MESH: Aged, 80 and over, Randomized controlled trial, law, MESH : Tumor Markers, Biological, Medicine, MESH : Neoplasm Staging, Orchiectomy, MESH : Orchiectomy, MESH : Prostate-Specific Antigen, MESH: Treatment Outcome, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH: Follow-Up Studies, MESH: Neoplasm Staging, Middle Aged, MESH : Survival Rate, 3. Good health, MESH: Prostate-Specific Antigen, Survival Rate, Prostate-specific antigen, MESH: Androgen Antagonists, Treatment Outcome, 030220 oncology & carcinogenesis, MESH : Prostatic Neoplasms, MESH : Time Factors, medicine.medical_specialty, MESH: Survival Rate, medicine.drug_class, Urology, MESH : Androgen Antagonists, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, 03 medical and health sciences, Internal medicine, Biomarkers, Tumor, Humans, MESH : Middle Aged, MESH : Aged, 80 and over, Survival rate, Aged, Neoplasm Staging, MESH: Humans, business.industry, MESH: Time Factors, MESH : Humans, Prostatic Neoplasms, Cancer, Androgen Antagonists, MESH : Follow-Up Studies, Prostate-Specific Antigen, Androgen, medicine.disease, MESH: Male, Surgery, MESH: Prostatic Neoplasms, MESH: Tumor Markers, Biological, business, Follow-Up Studies
Abstract: OBJECTIVE: EORTC trial 30891 compared immediate versus deferred androgen-deprivation therapy (ADT) in T0-4 N0-2 M0 prostate cancer (PCa). Many patients randomly assigned to deferred ADT did not require ADT because they died before becoming symptomatic. The question arises whether serum prostate-specific antigen (PSA) levels may be used to decide when to initiate ADT in PCa not suitable for local curative treatment. METHODS: PSA data at baseline, PSA doubling time (PSADT) in patients receiving no ADT, and time to PSA relapse (>2 ng/ml) in patients whose PSA declined to 50 ng/ml were at a>3.5-fold higher risk to die of PCa than patients with a baseline PSA12 mo. Time to PSA relapse after response to immediate ADT correlated significantly with baseline PSA, suggesting that baseline PSA may also reflect disease aggressiveness. CONCLUSIONS: Patients with a baseline PSA>50 ng/ml and/or a PSADT12 mo) were likely to die of causes unrelated to PCa, and thus could be spared the burden of immediate ADT.
Published: 2008

29. The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients

Author: Richard Delarue, Mathilde Hunault-Berger, Olivier Tournilhac, Arnaud Jaccard, Philippe Rodon, Pierre Morel, Marc Bernard, Arnaud Hot, Mohamed Hamidou, Benjamin Terrier, Fadi Fakhouri, Olivier Gisserot, Jean-Paul Fermand, Bernard Grosbois, Caroline Elie, Jacques Dantal, Véronique Leblond, Valérie Coiteux, Jean-Luc Harousseau, Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations (PMRIL), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Centre National de la Recherche Scientifique (CNRS), Service d'Hématologie biologique [CHU Limoges], CHU Limoges, Service d'immuno-hématologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Fédération des maladies infectieuses, CHU Clermont-Ferrand, Immunointervention dans les allo et xénotransplantations, Université de Nantes (UN)-IFR26-Institut National de la Santé et de la Recherche Médicale (INSERM)-ITUN, Institut de transplantation et de recherche en transplantation (ITERT), Laboratoire Hubert Curien [Saint Etienne] (LHC), Institut d'Optique Graduate School (IOGS)-Université Jean Monnet [Saint-Étienne] (UJM)-Centre National de la Recherche Scientifique (CNRS), Service de Médecine interne et immunologie clinique [Rennes] = internal medicine and clinical immunology [Rennes], CHU Pontchaillou [Rennes], Laboratoire de physique des milieux ionisés et applications (LPMIA), Université Henri Poincaré - Nancy 1 (UHP)-Centre National de la Recherche Scientifique (CNRS), Service d'immunologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Service de néphrologie pédiatrique [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service de médecine interne, Physique des milieux ionisés et applications (LPMIA), Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Physiologie Moléculaire de la Réponse Immune et des Lymphoproliférations ( PMRIL ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Université de Nantes ( UN ) -IFR26-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -ITUN, Institut de transplantation et de recherche en transplantation ( ITERT ), Laboratoire Hubert Curien [Saint Etienne] ( LHC ), Institut d'Optique Graduate School ( IOGS ) -Université Jean Monnet [Saint-Étienne] ( UJM ) -Centre National de la Recherche Scientifique ( CNRS ), Physique des milieux ionisés et applications ( LPMIA ), Université Henri Poincaré - Nancy 1 ( UHP ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], and CHU Necker - Enfants Malades [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP)
Subjects: Male, Pathology, MESH: Remission Induction, MESH : Retrospective Studies, medicine.medical_treatment, MESH : Aged, MESH : Alkylating Agents, MESH: Antigens, CD20, Hematopoietic stem cell transplantation, Gastroenterology, MESH: Antibodies, Monoclonal, 0302 clinical medicine, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH: Treatment Outcome, Aged, 80 and over, MESH: Middle Aged, MESH: Heart Diseases, Amyloidosis, MESH: Immunologic Factors, Remission Induction, Hematopoietic Stem Cell Transplantation, Antibodies, Monoclonal, General Medicine, MESH: Immunoglobulin M, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, MESH : Paraproteinemias, Rituximab, medicine.medical_specialty, Alkylating Agents, MESH: Serum Albumin, 03 medical and health sciences, MESH: Lymphatic Diseases, MESH : Antigens, CD20, MESH : Hematopoietic Stem Cell Transplantation, AL amyloidosis, Humans, Immunologic Factors, MESH : Middle Aged, MESH : Aged, 80 and over, Lymphatic Diseases, Aged, Retrospective Studies, MESH: Humans, MESH : Humans, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH : Amyloidosis, Complication, MESH: Female, Lung Diseases, Paraproteinemias, Antibodies, Monoclonal, Murine-Derived, MESH: Lung Diseases, MESH: Paraproteinemias, MESH: Aged, 80 and over, MESH : Purines, MESH : Female, Prospective cohort study, MESH: Aged, MESH : Lung Diseases, MESH : Lymphatic Diseases, MESH: Purines, Middle Aged, MESH : Adult, MESH : Survival Rate, Hematologic Response, MESH: Alkylating Agents, Treatment Outcome, MESH : Antibodies, Monoclonal, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, France, medicine.drug, Adult, Heart Diseases, MESH: Survival Rate, MESH : Immunoglobulin M, MESH : Male, MESH : Treatment Outcome, MESH : Immunologic Factors, MESH : Serum Albumin, Internal medicine, medicine, MESH: Amyloidosis, MESH : France, Serum Albumin, MESH: Hematopoietic Stem Cell Transplantation, MESH : Remission Induction, business.industry, Retrospective cohort study, MESH : Heart Diseases, Antigens, CD20, MESH: Male, MESH: France, Immunoglobulin M, Purines, business, 030215 immunology
Abstract: International audience; Immunoglobulin M (IgM)-related amyloidosis remains a rare and little-known complication of monoclonal IgM-associated disorders. We sought to determine the clinical and laboratory presentation, response to treatment, and outcome of patients with IgM-related amyloidosis in the era of new therapeutic approaches. We conducted a retrospective study in 29 French centers to identify patients with monoclonal IgM and biopsy-proven amyloidosis; we reviewed patients' records and collected relevant clinical and laboratory data. We identified 72 patients with IgM-related amyloidosis. Systemic primary amyloidosis (AL) was present in 64, peritumoral AL in 5, and systemic secondary amyloidosis (AA) in 3 patients. A peculiar pattern of relatively frequent lymph node (31%) and lung (17%) involvement was noted in patients with systemic AL amyloidosis. Response to alkylating agents was poor, with a hematologic response in 37%, a complete remission in 0%, and an organ response in 21%. Response to hematopoietic stem cell transplantation showed a hematologic response in 100% with complete remission in 75% and an organ response in 75%. Purine analogs and rituximab induced a hematologic response in 73% and 60%, respectively, with complete remission in 9% and 0% and an organ response in 55% and 0%, respectively. In multivariate analysis, prognostic factors for survival were serum albumin level < or =3.5 g/dL (p = 0.018) and heart involvement (p = 0.0034). Further prospective studies are needed in patients with IgM-related amyloidosis, with special emphasis on treatment options: hematopoietic stem cell transplantation and purine analogs could represent the most effective therapies. The identification of adverse prognostic factors of survival could be useful for those managing and making treatment decisions for these patients.
Published: 2008

30. Rurality and survival differences in lung cancer: a large population-based multivariate analysis

Author: Arlette Danzon, Jean-Luc Breton, Jean Lahourcade, Astrid Pozet, Mariette Mercier, Jean-Charles Dalphin, Pascal Berion, Didier Debieuvre, Alain Monnier, Virginie Westeel, Théoriser et modéliser pour aménager ( ThéMA ), Université de Bourgogne ( UB ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), FRANCIM, Réseau des registres français du cancer, Service de Pneumologie, CHI de la Haute-Saône, Centre Hospitalier de Belfort-Montbéliard, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Théoriser et modéliser pour aménager (UMR 6049) (ThéMA), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS)-Université de Bourgogne (UB), CH Belfort-Montbéliard, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), and Laboratoire Chrono-environnement - CNRS - UFC (UMR 6249) (LCE)
Subjects: Male, Rural Population, Cancer Research, Pediatrics, Lung Neoplasms, Multivariate analysis, MESH: Registries, MESH : Aged, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, 0302 clinical medicine, Rurality, MESH: Aged, 80 and over, MESH: Rural Population, Risk Factors, MESH: Risk Factors, MESH : Female, Registries, 030212 general & internal medicine, Prospective cohort study, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, MESH : Prognosis, Rural health, 1. No poverty, Middle Aged, MESH : Adult, Prognosis, MESH : Survival Rate, MESH : Risk Factors, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, MESH: Disease Progression, France, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, MESH: Multivariate Analysis, MESH: Prognosis, 03 medical and health sciences, medicine, Humans, MESH : Middle Aged, MESH : Lung Neoplasms, MESH : France, MESH : Aged, 80 and over, Aged, MESH: Humans, Proportional hazards model, business.industry, MESH : Humans, MESH : Multivariate Analysis, MESH: Adult, MESH : Disease Progression, Confidence interval, MESH: Male, Cancer registry, MESH: Lung Neoplasms, MESH: France, MESH : Rural Population, Multivariate Analysis, Rural area, business, MESH: Female, MESH : Registries, [ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, Demography
Abstract: International audience; Several studies have suggested rural health disadvantages. In France, studies on rural-urban patterns of lung cancer survival have yielded conflicting results. The aim of this analysis was to determine whether rural residence was associated with poor survival in three French counties. The database consisted of all primary lung cancer cases diagnosed in 2000 and 2001 collected through the Doubs cancer registry. A degree of rurality, obtained from socio-demographic and farming parameters of the 1999 French census treated with factor analysis, was attributed to each patient according to his/her place of residence. Among the 802 patients, 21% resided in rural areas, 11% were semi-urban inhabitants and 68% were urban residents. Survival differed significantly between these three rurality categories (p=0.04), with 2-year survival rates of 18, 29 and 24%, respectively. Using a Cox model, rural areas were significantly correlated with poor survival as compared with semi-urban areas (OR=1.42; 95% confidence interval=1.06-1.90; p=0.02). There was no survival difference between semi-urban and urban patients (OR=1.18; 95% confidence interval=0.91-1.53; p=0.21). Patient and tumour characteristics, especially stage and staging procedures, as well as first line treatment, did not vary with the degree of rurality. In conclusion, rurality has to be considered as a strong prognostic factor. Several intricate factors might be hypothesized such as increasing time to diagnosis leading to heavier tumour burden, worse treatment compliance and socioeconomic status. Before practical interventions can be proposed, prospective studies are warranted with further definition of rural risk factors for decreased survival in rural lung cancer patients.
Published: 2008

31. Trends in incidence of digestive cancers in France

Author: Anne-Marie Bouvier, Brigitte Trétarre, Jean Faivre, Marc Colonna, Michel Velten, Laurent Remontet, Florence Molinié, Côme Lepage, A. Buemi, Arlette Danzon, Nabil Maarouf, Guy Launoy, Nadine Bossard, Pascale Grosclaude, Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Service de Biostatistique des Hospices Civils de Lyon, Hospices Civils de Lyon ( HCL ), Registre des Tumeurs Digestives [Caen], Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, Registre des cancers de l'Hérault, Registre des Cancers du Tarn, Registre des cancers du Tarn, Registre des Cancers de l'Isère, CHU Grenoble, Registre des cancers du Bas-Rhin, Registre des Cancers du Haut-Rhin, Assoc. pour la recherche épidémiologique par les registres dans le Haut-Rhin, Registre des tumeurs du Doubs, Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Registre des cancers de Loire-Atlantique, Registre des cancers de la Manche, registre des cancers de la Manche, FRANCIM, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Hospices Civils de Lyon (HCL), Registre des Tumeurs Digestives [CHU Caen], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Registre des tumeurs du Doubs et du Territoire de Belfort [CHRU Besançon], Pôle cancérologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHPC - Site Louis Pasteur, Centre Hospitalier Public du Cotentin (CHPC)-Centre Hospitalier Public du Cotentin (CHPC), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Registre général des cancers du Tarn, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Registre des cancers de la Manche [CHPC - Site Louis Pasteur], Site Louis Pasteur [CHPC], CH Centre Hospitalier Public du Cotentin (CHPC)-CH Centre Hospitalier Public du Cotentin (CHPC), and Vesin, Aurélien
Subjects: Male, Cancer Research, MESH: Registries, Epidemiology, MESH : Mortality, Digestive System Neoplasms, Cohort Studies, 0302 clinical medicine, Risk Factors, MESH: Risk Factors, MESH : Population Surveillance, Mass Screening, Cumulative incidence, MESH : Female, Registries, MESH: Incidence, Stomach cancer, Digestive cancer, MESH: Cohort Studies, MESH : Sex Distribution, education.field_of_study, Incidence, Incidence (epidemiology), Mortality rate, MESH: Sex Distribution, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Survival Rate, MESH : Risk Factors, MESH : Incidence, 3. Good health, Survival Rate, Oncology, Population Surveillance, 030220 oncology & carcinogenesis, Female, 030211 gastroenterology & hepatology, France, [SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT], medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Population, MESH : Cohort Studies, MESH: Population Surveillance, 03 medical and health sciences, medicine, Humans, MESH: Mass Screening, Mortality, Sex Distribution, education, MESH : France, MESH : Mass Screening, MESH: Humans, MESH: Mortality, business.industry, MESH: Digestive System Neoplasms, MESH : Humans, Public Health, Environmental and Occupational Health, Cancer, medicine.disease, MESH: Male, Surgery, MESH: France, Standardized mortality ratio, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, MESH : Digestive System Neoplasms, business, MESH: Female, MESH : Registries, Demography
Abstract: International audience; The objective of this study was to analyse trends in the incidence of digestive cancers in France. Observed incidence and mortality data in the population covered by cancer registries were modelled using age-cohort models. An estimation of the incidence/mortality ratio was obtained from these models and was applied to the mortality rates predicted from an age-cohort model for the entire French population. Site-specific standardized-incidence rates by 1-year intervals and cumulative rate 0-74 years by birth cohort were estimated. On average, age-standardized incidence rates of large bowel cancers increased by 1.0% per year in men and 0.8% in women from 1980 to 2000. The estimated cumulative rate increased from 4.0% for men born in 1913 to 4.8% for those born in 1953. The corresponding values in women were 2.5 and 2.9%. The most striking increase in incidence was seen for primary liver cancer with an increase from 2000 incident cases in 1980 to nearly 6000 in 2000. The estimated cumulative rate was 0.5% for men born in 1913 and 2.9% for those born in 1953. The increase in incidence was lower for pancreas cancer. A decrease in the incidence of stomach cancer was observed for both sexes and of oesophageal cancer in men by slightly more than 2%. The study showed large changes in the cancer burden in France between 1980 and 2000.
Published: 2008

32. Treatment of Churg-Strauss syndrome without poor-prognosis factors: a multicenter, prospective, randomized, open-label study of seventy-two patients

Author: Camillo Ribi, Pascal Cohen, Jean-Pierre Arène, Christian Pagnoux, Loïc Guillevin, Xavier Puéchal, Philippe Delaval, Philippe Letellier, Jean-François Cordier, Dominique Lauque, Alfred Mahr, Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de médecine interne et centre de référence des maladies rares [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Signalisation et Réponses aux Agents Infectieux et Chimiques (SeRAIC), Université de Rennes (UR), CHU Pontchaillou [Rennes], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES), Hôpital Pontchaillou, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Signalisation et Réponses aux Agents Infectieux et Chimiques ( SeRAIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -IFR140, and Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes]
Subjects: Male, MESH: Remission Induction, OCCLUSION, MESH : Recurrence, medicine.medical_treatment, MESH : Aged, MESH : Prospective Studies, 0302 clinical medicine, MESH : Azathioprine, Azathioprine, Pharmacology (medical), Prospective Studies, MESH : Immunosuppressive Agents, MESH: Treatment Outcome, MESH: Middle Aged, MESH : Churg-Strauss Syndrome, Remission Induction, POLYARTERITIS-NODOSA, MESH : Pulse Therapy, Drug, Prognosis, 3. Good health, Survival Rate, Predictive value of tests, MESH: Administration, Oral, TRIAL, MESH: Immunosuppressive Agents, medicine.medical_specialty, Immunology, Disease-Free Survival, MESH: Prognosis, 03 medical and health sciences, Rheumatology, [ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology, PATIENTS, Humans, MESH : Middle Aged, MESH : Predictive Value of Tests, Adverse effect, MESH: Azathioprine, Aged, MESH: Humans, MESH : Humans, MESH: Cyclophosphamide, MESH: Adult, medicine.disease, MESH: Injections, Intravenous, Pulse Therapy, Drug, MESH: Disease-Free Survival, MESH: Pulse Therapy, Drug, MESH: Female, Administration, Oral, ANTINEUTROPHIL CYTOPLASMIC ANTIBODIES, Churg-Strauss Syndrome, Recurrence, MESH : Injections, Intravenous, CYCLOPHOSPHAMIDE, Immunology and Allergy, MESH : Female, 030212 general & internal medicine, Prospective cohort study, MESH : Cyclophosphamide, MESH: Aged, MESH : Prognosis, Immunosuppression, MESH : Adult, Middle Aged, MESH : Survival Rate, MESH: Predictive Value of Tests, MESH: Churg-Strauss Syndrome, Treatment Outcome, Injections, Intravenous, MESH : Disease-Free Survival, Female, Immunosuppressive Agents, medicine.drug, Adult, Cyclophosphamide, MESH: Survival Rate, MESH : Male, MESH : Treatment Outcome, SYSTEMIC NECROTIZING VASCULITIS, Predictive Value of Tests, Internal medicine, medicine, Survival rate, TERM-FOLLOW-UP, 030203 arthritis & rheumatology, MESH : Remission Induction, MESH : Administration, Oral, Vascular disease, business.industry, MESH: Male, MESH: Prospective Studies, Surgery, MESH: Recurrence, THROMBOSIS, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract: International audience; OBJECTIVE: To assess the efficacy of systemic corticosteroids (CS) alone as first-line treatment in patients with Churg-Strauss syndrome (CSS) without poor-prognosis factors, as defined by the Five-Factors Score (FFS), and to compare the efficacy and safety of oral azathioprine (AZA) versus intravenous pulse cyclophosphamide (CYC) as adjuvant immunosuppressive therapy for treatment failure or relapse. METHODS: This multicenter, prospective, randomized, open-label therapeutic trial included 72 patients with newly diagnosed CSS (FFS of 0) treated with CS alone. At treatment failure or relapse, patients were randomized to receive 6 months of oral AZA or 6 pulses of CYC. Analyses were performed according to an intent-to-treat strategy. RESULTS: The mean +/- SD followup was 56.2 +/- 31.7 months. Among the 72 patients studied, 93% achieved remission with CS therapy alone, and 35% relapsed, mainly during the first year of treatment. Among the 19 patients randomized to additional immunosuppression because of treatment failure or relapse, 5 of 10 receiving AZA and 7 of 9 receiving pulse CYC achieved remission, but the difference was not statistically significant. Survival rates in all patients at 1 and 5 years were 100% and 97%, respectively. At the end of followup, 79% of the patients whose disease was in remission required low-dose CS therapy, mainly to control respiratory disease. CS-related adverse events were observed in 31% of the 72 patients. CONCLUSION: In CSS patients with an FFS of 0, survival was excellent, confirming the predictive value of the FFS in this disease. First-line therapy with CS achieved remission in most patients, but relapses were common, and one-third of them required additional immunosuppressive therapy. AZA or pulse CYC was fairly effective in treating CS-resistant disease or major relapses. Over the long term, most patients continued to take oral CS, which might explain the high rate of CS-related adverse events.
Published: 2008

33. The influence of socio-economic and surveillance characteristics on breast cancer survival: a French population-based study

Author: Arlette Danzon, Patrick Arveux, Pascale Grosclaude, Michel Velten, Gilles Chaplain, Marc Colonna, Franck Bonnetain, Julie Gentil-Brevet, Registre des Cancers du Sein et autres Cancers Gynécologiques de Côte d'Or - Breast and Gynaecologic Cancer Registry of Côte d’Or, Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Registre des Cancers de l'Isère, CHU Grenoble, Registre des tumeurs du Doubs, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Cancéropôle du Grand Est, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Registre des Cancers du Tarn, Registre des cancers du Tarn, Registre des cancers du Bas-Rhin, CRLCC Paul Strauss, Vesin, Aurélien, Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Registre des tumeurs du Doubs et du Territoire de Belfort [CHRU Besançon], Pôle cancérologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Registre général des cancers du Tarn, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO)
Subjects: Oncology, Cancer Research, Epidemiology, MESH : Aged, MESH : Breast Neoplasms, Logistic regression, survival analysis, 0302 clinical medicine, MESH: Aged, 80 and over, MESH : Population Surveillance, MESH : Socioeconomic Factors, Medicine, MESH : Female, 030212 general & internal medicine, Aged, 80 and over, MESH: Aged, MESH: Middle Aged, medicine.diagnostic_test, Carcinoma, Ductal, Breast, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, MESH: European Continental Ancestry Group, MESH: Follow-Up Studies, Middle Aged, MESH : Adult, MESH : Survival Rate, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, Population Surveillance, Female, mass screening, Adult, medicine.medical_specialty, MESH: Socioeconomic Factors, MESH: Survival Rate, mammography, MESH: Mammography, Breast Neoplasms, White People, MESH: Population Surveillance, MESH : European Continental Ancestry Group, 03 medical and health sciences, Breast cancer, breast neoplasm, Internal medicine, Mammography, Humans, MESH : Mammography, MESH : Middle Aged, MESH: Mass Screening, MESH : Aged, 80 and over, Survival rate, Mass screening, Survival analysis, Aged, Gynecology, MESH : Mass Screening, MESH: Humans, business.industry, Proportional hazards model, MESH : Humans, MESH : Carcinoma, Ductal, Breast, Cancer, MESH: Adult, MESH : Follow-Up Studies, medicine.disease, MESH: Carcinoma, Ductal, Breast, Socioeconomic Factors, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, socio-economic factors, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, MESH: Breast Neoplasms, Follow-Up Studies
Abstract: International audience; Survival data on female invasive breast cancer with 9-year follow-up from five French cancer registries were analysed by logistic regression for prognostic factors of cancer stage. The Kaplan-Meier method and log-rank test were used to estimate and compare the overall survival probability at 5 and 7 years, and at the endpoint. The Cox regression model was used for multivariate analysis. County of residence, age group, occupational status, mammographic surveillance, gynaecological prevention consultations and the diagnosis mammography, whether within a screening framework or not, were independent prognostic factors of survival. Moreover, for the same age group, and only for cancers T2 and/or N+ (whether 1, 2 or 3) and M0, the prognosis was significantly better when the diagnosis mammography was done within the framework of screening. Socio-economic and surveillance characteristics are independent prognostic factors of both breast cancer stage at diagnosis and of survival. Screening mammography is an independent prognostic factor of survival.
Published: 2008

34. Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement

Author: Jean-Jacques Mazeron, M. Martin, E. Haddad, Pierre Géhanno, Jocelyne Huet, Catherine Durdux, René-Jean Bensadoun, Séverine Racadot, Christian Diana, G. Calais, Catherine Journel, Michel Henry-Amar, V. Favrel, Brigitte Blaska-Jaulerry, Sophie Dussart, François Baillet, Martin Housset, Christophe Hennequin, Bernadette Dessard-Diana, Gérard Pillet, Mariette Mercier, Emmanuelle Malaurie, Centre Alexis Vautrin ( CAV ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire Pierre Süe ( LPS ), Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Universite Antonine ( UPA ), Université Antonine, Centre Alexis Vautrin (CAV), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Pierre Süe (LPS), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Université Antonine (UA), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), and Universite Antonine (UPA)
Subjects: Male, MESH: Combined Modality Therapy, MESH: Lymphatic Metastasis, medicine.medical_treatment, MESH: Laryngeal Neoplasms, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Carboplatin, MESH: Proportional Hazards Models, chemistry.chemical_compound, 0302 clinical medicine, MESH : Oropharyngeal Neoplasms, MESH: Carboplatin, MESH : Female, MESH : Carcinoma, Squamous Cell, Neoplasm Metastasis, MESH: Radiotherapy Dosage, 030223 otorhinolaryngology, Lymph node, MESH: Treatment Outcome, MESH : Laryngeal Neoplasms, education.field_of_study, MESH: Middle Aged, MESH : Radiotherapy Dosage, Hazard ratio, MESH: Carcinoma, Squamous Cell, MESH : Lymphatic Metastasis, Radiotherapy Dosage, Hematology, Middle Aged, MESH : Survival Rate, Combined Modality Therapy, 3. Good health, Survival Rate, MESH : Antineoplastic Agents, Oropharyngeal Neoplasms, medicine.anatomical_structure, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, MESH : Carboplatin, Lymphatic Metastasis, MESH : Neoplasm Metastasis, Carcinoma, Squamous Cell, Female, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Population, [SDV.CAN]Life Sciences [q-bio]/Cancer, Antineoplastic Agents, MESH : Treatment Outcome, 03 medical and health sciences, medicine, Humans, Radiology, Nuclear Medicine and imaging, MESH : Middle Aged, education, Survival rate, Laryngeal Neoplasms, Proportional Hazards Models, Chemotherapy, MESH: Humans, business.industry, MESH : Humans, MESH : Proportional Hazards Models, MESH: Neoplasm Metastasis, MESH: Male, Surgery, Radiation therapy, MESH: Oropharyngeal Neoplasms, chemistry, Concomitant, MESH: Antineoplastic Agents, business, MESH : Combined Modality Therapy, MESH: Female
Abstract: International audience; BACKGROUND AND PURPOSE: Post-operative radiotherapy is indicated for the treatment of head and neck cancers. In vitro, chemotherapy potentiates the cytotoxic effects of radiation. We report the results of a randomized trial testing post-operative radiotherapy alone versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement. MATERIALS AND METHODS: The study involved patients undergoing curative-intent surgery for head and neck cancers with histological evidence of lymph node involvement. Patients were randomly assigned to receive radiotherapy alone (54-72Gy, 30-40 fractions, 6-8 weeks) or identical treatment plus concomitant Carboplatin (50mg/m(2) administered by IV infusion twice weekly). RESULTS: Between February 1994 and June 2002, 144 patients were included. With a median follow-up of 106 months (95% confidence interval (CI) [92-119]), the 2-year rate of loco-regional control was 73% (95% CI: 0.61-0.84) in the combined treatment group and 68% (95% CI: 0.57-0.80) in the radiotherapy group (p=0.26). Overall survival did not differ significantly between groups (hazard ratio for death, 1.05; 95% CI: 0.69-1.60; p=0.81). CONCLUSIONS: Twice-weekly administration of carboplatin concomitant to post-operative radiotherapy did not improve local control or overall survival rates in this population of patients with node-positive head and neck cancers.
Published: 2007

35. Propionibacterium endocarditis: a case series from the International Collaboration on Endocarditis Merged Database and Prospective Cohort Study

Author: Tahaniyat Lalani, Anna K. Person, Susan S. Hedayati, Laura Moore, David R. Murdoch, Bruno Hoen, Gail Peterson, Hasan Shahbaz, Didier Raoult, Jose M. Miro, Lars Olaison, Ulrika Snygg-Martin, Fredy Suter, Dennis Spelman, Susannah Eykyn, Jacob Strahilevitz, Jan T. Van Der Meer, Dominique Verhagen, Khaula Baloch, Elias Abrutyn, Christopher H. Cabell, null The International Collaboration On, Amsterdam institute for Infection and Immunity, Infectious diseases, Service des maladies infectieuses et tropicales, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Centre National de la Recherche Scientifique (CNRS)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Unité des Rickettsies et pathogènes émergents (URPE), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (URMITE), Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, INSB-INSB-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Unité des Rickettsies et pathogènes émergents ( URPE ), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes ( URMITE ), Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR48, INSB-INSB-Centre National de la Recherche Scientifique ( CNRS ) -Institut de Recherche pour le Développement ( IRD ) -Aix Marseille Université ( AMU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -IFR48, INSB-INSB-Centre National de la Recherche Scientifique ( CNRS ), Laboratoire Chrono-environnement (UMR 6249) (LCE), Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR48, and Institut des sciences biologiques (INSB-CNRS)-Institut des sciences biologiques (INSB-CNRS)-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Heart disease, Databases, Factual, MESH : International Cooperation, International Cooperation, MESH : Prospective Studies, MESH : Aged, 030204 cardiovascular system & hematology, computer.software_genre, Cohort Studies, 0302 clinical medicine, MESH: Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, MESH : Actinomycetales Infections, MESH : Female, 030212 general & internal medicine, Prospective Studies, MESH : Endocarditis, Bacterial, Abscess, Prospective cohort study, MESH: Cohort Studies, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Database, MESH: Heart Diseases, General Medicine, MESH : Adult, Middle Aged, MESH : Survival Rate, Prognosis, MESH : Risk Factors, 3. Good health, Survival Rate, [ SDV.MHEP.MI ] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Infectious Diseases, medicine.anatomical_structure, MESH: Propionibacterium, Infective endocarditis, Heart Valve Prosthesis, Female, Actinomycetales Infections, Cohort study, Microbiology (medical), Adult, medicine.medical_specialty, Prosthesis-Related Infections, MESH: Survival Rate, MESH: Heart Valve Prosthesis, Heart Diseases, MESH : Male, MESH : Cohort Studies, MESH : Databases, Factual, MESH: Prognosis, MESH : Prosthesis-Related Infections, MESH : Heart Valve Prosthesis, 03 medical and health sciences, medicine, Endocarditis, Humans, MESH : Middle Aged, Heart valve, MESH: Endocarditis, Bacterial, Aged, MESH: Humans, General Immunology and Microbiology, business.industry, MESH: Prosthesis-Related Infections, MESH : Humans, Propionibacterium, MESH : Heart Diseases, MESH: Adult, Endocarditis, Bacterial, medicine.disease, MESH: Databases, Factual, MESH: Male, MESH: Prospective Studies, Surgery, MESH: International Cooperation, Heart failure, business, computer, MESH: Female, MESH : Propionibacterium, MESH: Actinomycetales Infections
Abstract: International audience; Propionibacterium species are occasionally associated with serious systemic infections such as infective endocarditis. In this study, we examined the clinical features, complications and outcome of 15 patients with Propionibacterium endocarditis using the International Collaboration on Endocarditis Merged Database (ICE-MD) and Prospective Cohort Study (ICE-PCS), and compared the results to 28 cases previously reported in the literature. In the ICE database, 11 of 15 patients were male with a mean age of 52 y. Prosthetic valve endocarditis occurred in 13 of 15 cases and 3 patients had a history of congenital heart disease. Clinical findings included valvular vegetations (9 patients), cardiac abscesses (3 patients), congestive heart failure (2 patients), and central nervous system emboli (2 patients). Most patients were treated with beta-lactam antibiotics alone or in combination for 4 to 6 weeks. 10 of the 15 patients underwent valve replacement surgery and 2 patients died. Similar findings were noted on review of the literature. The results of this paper suggest that risk factors for Propionibacterium endocarditis include male gender, presence of prosthetic valves and congenital heart disease. The clinical course is characterized by complications such as valvular dehiscence, cardiac abscesses and congestive heart failure. Treatment may require a combination of medical and surgical therapy.
Published: 2007

36. Cancer prevalence in France: time trend, situation in 2002 and extrapolation to 2012

Author: Guy Launoy, Anne-Valérie Guizard, N. Mitton, Michel Velten, Arlette Danzon, Erik-André Sauleau, Olivier Ganry, Simona Bara, Claire Schvartz, Brigitte Trétarre, Anne-Marie Bouvier, Patricia Delafosse, Marc Colonna, Pascale Grosclaude, Florence Molinié, Registre des Cancers de l'Isère, CHU Grenoble, Registre des tumeurs du Doubs et du Territoire de Belfort [CHRU Besançon], Pôle cancérologie (CHRU Besançon), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Registre des cancers de la Manche, CHPC - Site Louis Pasteur, Centre Hospitalier Public du Cotentin (CHPC)-Centre Hospitalier Public du Cotentin (CHPC), Registre Bourguignon des Cancers Digestifs, Lipides - Nutrition - Cancer (U866) (LNC), Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Université de Bourgogne (UB)-Institut National de la Santé et de la Recherche Médicale (INSERM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon (ENSBANA)-Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Registre général des cancers de la Somme, CHU Amiens-Picardie, Registre des cancers du Calvados, Registre des Tumeurs Digestives [CHU Caen], Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-Université de Caen Normandie (UNICAEN), Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN), Registre des cancers de Loire-Atlantique, Registre des cancers du Haut-Rhin, Registre des cancers thyroïdiens de Marne-Ardenne, Registre des cancers du Bas-Rhin, CRLCC Paul Strauss, Registre des cancers du Tarn, Registre des cancers du Calvados de l'Hérault, Registre des tumeurs du Doubs, Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), registre des cancers de la Manche, Lipides - Nutrition - Cancer (U866) ( LNC ), Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Université de Bourgogne ( UB ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Ecole Nationale Supérieure de Biologie Appliquée à la Nutrition et à l'Alimentation de Dijon ( ENSBANA ) -Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Registre des Cancers de la Somme, Registre des Tumeurs Digestives [Caen], Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -CHU Caen, Vesin, Aurélien, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Registre des cancers de la Manche [CHPC - Site Louis Pasteur], Site Louis Pasteur [CHPC], CH Centre Hospitalier Public du Cotentin (CHPC)-CH Centre Hospitalier Public du Cotentin (CHPC), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Registre général des cancers du Tarn, and Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)
Subjects: Male, Cancer Research, Pathology, MESH: Registries, MESH : Prevalence, Prevalence, MESH : Aged, MESH : Age Distribution, 0302 clinical medicine, Prostate, Neoplasms, Epidemiology, MESH : Female, MESH: Neoplasms, 030212 general & internal medicine, MESH: Incidence, Registries, MESH: Aged, education.field_of_study, MESH: Middle Aged, Incidence (epidemiology), Incidence, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Middle Aged, MESH : Survival Rate, MESH : Incidence, 3. Good health, Survival Rate, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, Female, France, MESH: Forecasting, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, Population, 03 medical and health sciences, Age Distribution, medicine, Humans, MESH : Middle Aged, MESH : Forecasting, education, MESH : France, Survival rate, MESH: Age Distribution, Cancer prevalence, MESH: Prevalence, Aged, MESH: Humans, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, MESH: Male, MESH: France, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, MESH: Female, MESH : Registries, Demography, Forecasting
Abstract: International audience; BACKGROUND: Cancer prevalence is a basic indicator of the cancer burden in a population and essential to estimate the resources needed for care of cancer patients. This paper provides a prevalence estimate for 2002 and 2012 in France and an assessment of the trend in prevalence over the period 1993-2002. METHOD: Incidence and survival data from French cancer registries were used to estimate specific 5-year partial prevalence rates that were then applied to the whole French population. RESULTS: In 2002, the 5-year partial prevalence was over 427,000 in men and 409,000 in women. The most frequent cancer site among men was prostate (35% of the cases) and breast in women (45% of the cases). In 2002, in France, more than 3.5% of men over 74 years old are alive with a prostatic cancer diagnosed within 5 years. The increase in the number of cases between 1993 and 2002 was about 40% and was mainly due to prostate and breast cancers. The demographic variations alone induce an increase of the number of prevalent cases of 75,000 among men and 54,500 among women if both incidence and survival are considered as stable during the period 2002-2012. CONCLUSION: This study uses a large amount of information from cancer registries which makes it possible to assess the cancer burden. Five-year prevalence is very sensitive to changes in incidence and demographic changes. Prevalence has to be estimated regularly in order to ensure accurate medical care meets demand.
Published: 2007

37. Immune modulation and microchimerism after unmodified versus leukoreduced allogeneic red blood cell transfusion in cancer patients: results of a randomized study

Author: Dominique Tramalloni, Philippe Saas, N. Oubouzar, Christophe Ferrand, Eric Robinet, Pierre Tiberghien, Valérie Lapierre, Anne Auperin, Philippe Lasser, Bertrand Debaene, Institut Gustave Roussy ( IGR ), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC ( HOTE GREFFON ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ) -Université de Franche-Comté ( UFC ), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( PCVP / CARDIO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), Laboratoire de biologie moléculaire, EFS, Plateforme de Biomonitoring, Etablissement français du sang [Bourgogne-France-Comté] ( EFS [Bourgogne-France-Comté] ), Institut Gustave Roussy (IGR), Interactions hôte-greffon-tumeur, ingénierie cellulaire et génique - UFC (UMR INSERM 1098) (RIGHT), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( EA 3920) (PCVP / CARDIO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté]), Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang [Bourgogne-Franche-Comté] (EFS [Bourgogne-Franche-Comté])-Université de Franche-Comté (UFC), Marqueurs pronostiques et facteurs de régulations des pathologies cardiaques et vasculaires - UFC ( UR 3920) (PCVP / CARDIO), and Saas, Philippe
Subjects: Male, Blood transfusion, Erythrocytes, medicine.medical_treatment, MESH : Cytokines, MESH : Leukocytes, MESH : Aged, 030204 cardiovascular system & hematology, Blood cell, Blood Transfusion, Autologous, 0302 clinical medicine, MESH: Blood Transfusion, Autologous, Neoplasms, Leukocytes, Immunology and Allergy, Medicine, [ SDV.IMM ] Life Sciences [q-bio]/Immunology, MESH: Neoplasms, MESH : Female, MESH: Aged, MESH: Cytokines, MESH: Middle Aged, MESH: Erythrocytes, MESH : Immune Tolerance, Interleukin, Microchimerism, Forkhead Transcription Factors, hemic and immune systems, Hematology, MESH: Follow-Up Studies, Middle Aged, MESH : Adult, MESH : Survival Rate, 3. Good health, Survival Rate, MESH : Erythrocyte Transfusion, MESH : Forkhead Transcription Factors, MESH : Phenotype, medicine.anatomical_structure, Phenotype, 030220 oncology & carcinogenesis, Cytokines, [SDV.IMM]Life Sciences [q-bio]/Immunology, Female, Erythrocyte Transfusion, circulatory and respiratory physiology, Adult, MESH: Immune Tolerance, [SDV.IMM] Life Sciences [q-bio]/Immunology, MESH: Survival Rate, MESH : Male, Immunology, MESH: Phenotype, Peripheral blood mononuclear cell, Chimerism, MESH: Leukocytes, 03 medical and health sciences, Immune system, MESH: Forkhead Transcription Factors, Immune Tolerance, Humans, MESH : Middle Aged, Aged, MESH : Blood Transfusion, Autologous, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, MESH : Follow-Up Studies, medicine.disease, MESH: Chimerism, MESH : Neoplasms, MESH: Male, Red blood cell, MESH: Erythrocyte Transfusion, MESH : Chimerism, business, MESH: Female, Follow-Up Studies, MESH : Erythrocytes
Abstract: International audience; BACKGROUND: Transfusion of red blood cells (RBCs) has been associated with immunomodulatory effects. Persistence of donor cells in the recipient may be contributive. STUDY DESIGN AND METHODS: A randomized single-center trial was conducted to compare microchimerism and immune responses in 35 patients undergoing cancer surgery and transfused perioperatively with either unmodified RBCs (UN-RBCs, n = 18) or leukoreduced RBCs (LR-RBCs, n = 17). Biologic parameters included microchimerism assessment peripheral blood mononuclear cell (PBMNC) phenotyping, cytokine production by stimulated PBMNCs, FoxP3 gene expression, and T-cell repertoire (TCR) analysis. RESULTS: Microchimerism was documented in 8 of 18 patients after UN-RBC transfusion while absent after LR-RBC transfusion (0/17; p = 0.001). After UN-RBC transfusion, microchimerism was associated with increased interleukin (IL)-10 production (p = 0.02), reduced TCR alteration (p = 0.04), and reduced CD56+ cell counts (p = 0.02) when compared to recipients without evidence for microchimerism. FoxP3 gene expression did not differ significantly between both treatment groups nor with the presence or absence of microchimerism in the UN-RBC group. Finally, after an initial early decrease after surgery and transfusion, IL-12 production increased and more significantly so after UN-RBC transfusion versus LR-RBC transfusion (p = 0.05). CONCLUSION: UN-RBC-induced microchimerism is associated with specific immunomodulatory effects in cancer patients who received transfusions during surgery.
Published: 2007

38. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01

Author: Jean Luc Breton, Virginie Westeel, Elisabeth Quoix, Dominique Maraninchi, Sabine Gameroff, Radj Gervais, Jean-Louis Pujol, H. Janicot, Philippe David, Jean Genève, Marie-Laure Tanguy, Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de pneumologie, CHU Strasbourg-Hopital Civil, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC), Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Centre François Baclesse, Service de biostatistiques et information médicale [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU), Département de Biostatistique, Santé Publique et Information Médicale [CHU Pitié-Salpêtrière] (BIOSPIM ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO)
Subjects: Male, Cancer Research, Lung Neoplasms, medicine.medical_treatment, Placebo-controlled study, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Proportional Hazards Models, 0302 clinical medicine, MESH : Female, MESH: Double-Blind Method, Carcinoma, Small Cell, Etoposide, 0303 health sciences, MESH: Middle Aged, MESH: Thalidomide, MESH: Carcinoma, Small Cell, Middle Aged, MESH : Survival Rate, Thalidomide, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, MESH : Disease-Free Survival, Female, medicine.drug, medicine.medical_specialty, Cyclophosphamide, MESH: Survival Rate, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, Placebo, Disease-Free Survival, MESH : Thalidomide, 03 medical and health sciences, Double-Blind Method, Internal medicine, medicine, Humans, MESH : Double-Blind Method, MESH : Middle Aged, MESH : Lung Neoplasms, Lung cancer, Survival rate, Proportional Hazards Models, 030304 developmental biology, Chemotherapy, MESH: Humans, business.industry, MESH : Humans, medicine.disease, MESH : Proportional Hazards Models, MESH: Male, Surgery, MESH : Carcinoma, Small Cell, MESH: Lung Neoplasms, MESH: Disease-Free Survival, business, MESH: Female
Abstract: Purpose This randomized, double-blind, placebo-controlled phase III study aimed to determine whether thalidomide prolongs survival of patients with extensive-disease small-cell lung cancer (SCLC). Patients and Methods One hundred nineteen patients received two courses of etoposide, cisplatin, cyclophosphamide, and 4′-epidoxorubicin (PCDE). Responder patients who had recovered from chemotherapy toxicity were randomly assigned to receive four additional PCDE cycles plus thalidomide (400 mg daily) or placebo. Results After the first two PCDE cycles, objective response rate was 81.5%, and 92 patients were randomly assigned to placebo (n = 43) or thalidomide (n = 49). Median exposure duration to placebo was 4.5 months, and median exposure to thalidomide was 4.9 months. Patients treated with thalidomide had a longer survival compared with patients who received placebo, although the difference was not statistically significant (minimal follow-up, 3 years; median survival time, 11.7 v 8.7 months, respectively; log-rank test: hazard ratio [HR] = 0.74; 95% CI, 0.49 to 1.12; P = .16). Patients with a performance status (PS) of 1 or 2 who received thalidomide had a significantly longer survival (HR = 0.59; 95% CI, 0.37 to 0.92; P = .02). The disease also progressed slower in patients with PS of 1 or 2 receiving thalidomide (HR = 0.54; 95% CI, 0.36 to 0.87; P = .02), whereas the difference did not reach statistical significance for the whole population (HR = 0.74; 95% CI, 0.49 to 1.12; P = .15). Neuropathy occurred more frequently in the thalidomide group compared with the placebo group (33% v 12%, respectively). Conclusion Treatment with thalidomide was not associated with a significant improvement in survival of SCLC patients. There was pronounced heterogeneity in survival outcomes between groups of patients. Some benefit was observed among patients with a PS of 1 or 2 (exploratory analyses), deserving further studies targeting angiogenesis in this disease.
Published: 2007

39. Negative impact of rurality on lung cancer survival in a population-based study

Author: Alexandre Pitard, Jean-Charles Dalphin, Patrick Arveux, Virginie Westeel, A. Depierre, Isabelle Thaon, Mael Martin, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire Chrono-environnement ( LCE ), Université Bourgogne Franche-Comté ( UBFC ) -Centre National de la Recherche Scientifique ( CNRS ) -Université de Franche-Comté ( UFC ), Registre des Cancers du Sein et autres Cancers Gynécologiques de Côte d'Or - Breast and Gynaecologic Cancer Registry of Côte d’Or, Centre d'épidémiologie des populations ( CEP ), Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ) -Université de Bourgogne ( UB ) -Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Registre des tumeurs du Doubs, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Cancéropôle du Grand Est, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Laboratoire Chrono-environnement - CNRS - UBFC (UMR 6249) (LCE), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre National de la Recherche Scientifique (CNRS), Centre d'épidémiologie des populations (CEP), Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER-Université de Bourgogne (UB)-Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER-UNICANCER, Registre des tumeurs du Doubs et du Territoire de Belfort [CHRU Besançon], Pôle cancérologie (CHRU Besançon), and Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: Male, Rural Population, Lung Neoplasms, Survival, MESH : Retrospective Studies, MESH : Aged, 0302 clinical medicine, Rurality, MESH: Aged, 80 and over, MESH: Rural Population, Risk Factors, MESH: Risk Factors, Medicine, Rural, MESH : Female, 030212 general & internal medicine, Aged, 80 and over, MESH: Aged, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, Relative survival, 1. No poverty, [ SDV.SPEE ] Life Sciences [q-bio]/Santé publique et épidémiologie, Middle Aged, Cancer registry, MESH : Adult, Prognosis, MESH : Survival Rate, MESH : Risk Factors, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Population study, Female, Medical emergency, France, Lung cancer, Adult, Pulmonary and Respiratory Medicine, MESH: Survival Rate, MESH : Male, Population, Prognostic factors, MESH: Prognosis, 03 medical and health sciences, Humans, MESH : Middle Aged, MESH : Lung Neoplasms, Risk factor, education, MESH : Aged, 80 and over, MESH : France, Aged, Retrospective Studies, MESH: Humans, business.industry, MESH : Humans, Cancer, MESH: Adult, MESH: Retrospective Studies, medicine.disease, MESH: Male, MESH: Lung Neoplasms, MESH: France, MESH : Rural Population, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Rural area, business, MESH: Female, Demography
Abstract: International audience; INTRODUCTION: Several studies have suggested that rurality is a risk factor for worse prognosis in cancer. METHODS: The study population included the 2268 lung cancer cases collected between 1981 and 1996 in the Doubs Cancer Registry (France). RESULTS: The numbers of patients were 849 (31.8%) in rural areas and 89 (3.3%) in very rural areas. The relative 5-year survival was 15.2% in rural areas and 13.4% in urban areas (p = 0.5), and 2.7% in very rural areas and 14.4% in extended urban areas (p = 0.02). Multivariate analyses of observed and relative survival showed that patients living in very rural areas (p < 0.0001), 65 years of age and older and having small cell carcinoma had a significantly shorter survival. CONCLUSIONS: This study showed that the multidimensional definition of rurality identified a population with unfavorable prognoses.
Published: 2007

40. Trends in cervical cancer survival in Europe, 1983-1994: a population-based study

Author: Bielska-Lasota, M., Inghelmann, R., van de Poll-Franse, L., Capocaccia, R., Storm, H. H., Aareleid, T., Jechova, M., Rousarova, M., Hakulinen, T., Hedelin, G., Tron, I., Le Gall, E., Launoy, G., Mace-Lesec'h, J., Faivre, J., Chaplain, G., Carli, P. -M., Danzon, A., Tretarre, B., Colonna, M., Lacour, B., Raverdy, N., Berger, C., Freycon, B., Grosclaude, P., Esteve, J., Kaatsch, P., Ziegler, H., Holzel, D., Schubert Fritschle, G., Tryggvadottir, L., Berrino, F., Allemani, C., Baili, P., Ciccolallo, L., Crosignani, P., Gatta, G., Micheli, A., Sant, M., Taussig, E., Sowe, S., Ferretti, S., Conti, E., Vercelli, M., Quaglia, A., Pannelli, F., Federico, M., Artioli, M. E., Ponz De Leon, M., Benatti, P., De Lisi, V., Servente, L., Zanetti, R., Patriarca, S., Magnani, C., Pastore, G., Gafa, L., Tumino, R., Falcini, F., Budroni, M., Paci, E., Crocetti, E., Zambon, P., Guzzinati, S., Carrani, E., De Angelis, R., Roazzi, P., Santaquilani, M., Tavilla, A., Valente, F., Verdecchia, A., Dalmas, M., Langmark, F., Andersen, A., Pinheiro, P., Rachtan, J., Wronkowski, Z., Zwierko, M., Plesko, I., Obsitnikova, A., Pompe-Kirn, V., Primic-Zakelj, M., Izarzugaza, I., Martinez-Garcia, C., Garau, I., Navarro, C., Chirlaque, M. D., Ardanaz, E., Moreno, C., Galceran, J., Torrella, A., Peris-Bonet, R., Barlow, L., Moller, T., Jundt, G., Lutz, J. M., Bouchardy, C., Coebergh, J. W. W., van der Does-van den Berg, A., Visser, O., Godward, S., Coleman, M. P., Williams, E. M. I., Forman, D., Quinn, M. J., Roche, M., Edwards, S., Stiller, C., Verne, J., Moller, H., Bell, J., Botha, H., Lawrence, G., Black, R., Steward, J. A., Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), and Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
Subjects: MESH: Registries, MESH : Mortality, MESH : Aged, Uterine Cervical Neoplasms, Disease, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aged, 80 and over, 0302 clinical medicine, MESH : Female, Registries, MESH: Aged, Cervical cancer, Aged, 80 and over, 0303 health sciences, education.field_of_study, MESH: Middle Aged, MESH : Prognosis, Relative survival, Absolute risk reduction, Obstetrics and Gynecology, Middle Aged, MESH : Adult, Prognosis, MESH : Survival Rate, 3. Good health, MESH: Uterine Cervical Neoplasms, Europe, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Adenocarcinoma, Female, Adult, medicine.medical_specialty, MESH: Survival Rate, Adolescent, Population, MESH : Uterine Cervical Neoplasms, MESH : Europe, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Prognosis, Trends - cervical cancer - survival, 03 medical and health sciences, MESH : Adolescent, medicine, Humans, MESH : Middle Aged, Mortality, education, MESH : Aged, 80 and over, Survival rate, 030304 developmental biology, Aged, MESH: Adolescent, Gynecology, MESH: Humans, MESH: Mortality, business.industry, MESH : Humans, Cancer, MESH: Adult, Population-based study, Survival, Trends, medicine.disease, MESH: Europe, business, MESH: Female, MESH : Registries, Demography
Abstract: International audience; OBJECTIVE: To evaluate trends in survival from cervical cancer in Europe and in European countries participating in the EUROCARE study as a function of age, morphology and stage at diagnosis. METHODS: Relative survival and relative excess risk of death within 5 years of diagnosis, as a function of age, morphology and stage, among 73,022 women aged 15-99 years diagnosed during 1983-1994 and followed up to 1999 in each of 18 European countries participating in the EUROCARE study, using data from 34 population-based cancer registries. RESULTS: Overall five-year relative survival was 62%, rising by 2% during the period 1983-1994. The highest survival occurred in Northern and Western Europe and the lowest in Central Europe. Survival falls with age at diagnosis, but mainly for localised disease. Survival is higher for adenocarcinoma in younger women, but higher for squamous cell carcinoma in older women. The proportions of younger women, localised cancer and adenocarcinoma all increased. The main improvements in survival were for women under 65, and for metastatic disease. CONCLUSIONS: Survival in Europe has improved slowly but steadily, but the trend is not geographically uniform. Central European countries and the UK saw little or no improvement, and survival in those countries remains the lowest among participating countries in Europe. Further reduction of cervical cancer mortality in Europe may be expected from expansion of screening, and improvement in the treatment of older women, and of metastatic disease.
Published: 2007

41. [IFCT-0302 trial: randomised study comparing two follow-up schedules in completely resected non-small cell lung cancer]

Author: Westeel , Virginie, Lebitasy , M. P., Mercier , Mariette, Girard , P., Barlesi , F., Blanchon , F., Tredaniel , J., Bonnette , P., Woronoff-Lemsi , M. C., Breton , J. L., Azarian , R., Falcoz , P. E., Friard , S., Geriniere , L., Laporte , S., Lemarie , E., Quoix , E., Zalcman , G., Guigay , J., Morin , F., Milleron , B., Depierre , A., Renseigné , Non, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Groupe de recherche sur la thrombose ( GRT (EA 3065) ), Université Jean Monnet [Saint-Étienne] ( UJM ), Institut de physiologie et biologie cellulaires ( IPBC ), Université de Poitiers-Centre National de la Recherche Scientifique ( CNRS ), Viala, Pascale, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Groupe de recherche sur la thrombose (GRT (EA 3065)), and Université Jean Monnet [Saint-Étienne] (UJM)
Subjects: MESH: Fiber Optic Technology, MESH: Neoplasms, Second Primary, Lung Neoplasms, MESH: Survival Rate, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Population Surveillance, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Physical Examination, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH : Fiber Optic Technology, Carcinoma, Non-Small-Cell Lung, Bronchoscopy, MESH : Tomography, X-Ray Computed, MESH : Population Surveillance, Fiber Optic Technology, Humans, MESH : Bronchoscopy, MESH: Bronchoscopy, MESH : Neoplasms, Second Primary, MESH : Lung Neoplasms, Physical Examination, MESH: Humans, MESH : Carcinoma, Non-Small-Cell Lung, MESH : Neoplasm Recurrence, Local, MESH : Physical Examination, MESH : Humans, MESH: Quality of Life, Neoplasms, Second Primary, MESH : Follow-Up Studies, MESH: Follow-Up Studies, MESH : Quality of Life, MESH: Radiography, Thoracic, MESH : Survival Rate, MESH : Radiography, Thoracic, MESH: Lung Neoplasms, Survival Rate, Population Surveillance, Quality of Life, Radiography, Thoracic, Neoplasm Recurrence, Local, MESH: Tomography, X-Ray Computed, Tomography, X-Ray Computed, MESH: Neoplasm Recurrence, Local, MESH: Carcinoma, Non-Small-Cell Lung, Follow-Up Studies
Abstract: International audience; BACKGROUND: The authorities advocate a minimalist attitude towards the follow-up of resected bronchial carcinoma (clinical examination and chest x-ray). A survey showed that 70% of French respiratory physicians have chosen to use the CT scanner and often endoscopy. The published data are equivocal and are often based on retrospective studies. Lung cancer is a good model for a study of post-operative surveillance. Recurrences often occur in easily observed areas, they may be detected while still asymptomatic and are sometimes potentially curable. Second primary tumours may develop at the same site. METHODS: The Intergroupe Francophone de Cancerologie Thoracique (IFCT) has initiated a trial comparing simple follow-up (clinical examination, chest x-ray) with a more intensive follow-up (CT scan, fibreoptic bronchoscopy). The surveillance will take place every 6 months for 2 years and then annually until 5 years. EXPECTED RESULTS: The main aim is to determine whether intensive follow-up improves patient survival. The opposite question is equally important. If an expensive and demanding follow-up does not affect the chances of cure these results will influence our practice.
Published: 2007

42. [Cancer incidence and survival among adolescents and young adults in France (1978-1997)]

Author: Emmanuel Desandes, Lacour B, Belot A, White-Koning M, Velten M, Tretarre B, Ea, Sauleau, Maarouf N, Av, Guizard, Delafosse P, Danzon A, Cotte C, Boutreux S, Brugières L, Centre Alexis Vautrin ( CAV ), Registre National des Tumeurs Solides de l'Enfant ( RNTSE ), Cancéropôle du Grand Est-Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), Service de Biostatistique, Hospices Civils de Lyon ( HCL ), Laboratoire de Biométrie et Biologie Evolutive ( LBBE ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique ( Inria ) -Centre National de la Recherche Scientifique ( CNRS ), Département des maladies chroniques et traumatismes, Institut de Veille Sanitaire (INVS), FRANCIM, Réseau des registres français du cancer, Registre des cancers de la Manche, registre des cancers de la Manche, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Cancers et Populations : Facteurs de Risque, Depistage, Pratiques Diagnostiques et Therapeutiques, Université de Caen Normandie ( UNICAEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Département de Pédiatrie, Institut Gustave Roussy ( IGR ), Centre Alexis Vautrin (CAV), Registre National des Tumeurs Solides de l'Enfant (RNTSE), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Cancéropôle du Grand Est, Hospices Civils de Lyon (HCL), Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), CHPC - Site Louis Pasteur, Centre Hospitalier Public du Cotentin (CHPC)-Centre Hospitalier Public du Cotentin (CHPC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Institut Gustave Roussy (IGR), Registre des cancers de la Manche [CHPC - Site Louis Pasteur], Site Louis Pasteur [CHPC], CH Centre Hospitalier Public du Cotentin (CHPC)-CH Centre Hospitalier Public du Cotentin (CHPC), and Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO)
Subjects: Adult, Male, Adolescent, MESH: Registries, MESH: Survival Rate, MESH : Male, MESH : Age Distribution, [SDV.CAN]Life Sciences [q-bio]/Cancer, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Cause of Death, Age Distribution, Cause of Death, Neoplasms, MESH : Adolescent, Humans, MESH: Neoplasms, MESH : Female, Registries, MESH: Incidence, Sex Distribution, MESH : France, MESH: Age Distribution, MESH : Sex Distribution, MESH : Cause of Death, MESH: Adolescent, MESH: Humans, Incidence, MESH: Sex Distribution, MESH : Humans, MESH: Adult, MESH : Adult, MESH : Survival Rate, Survival Analysis, MESH : Neoplasms, MESH: Male, MESH : Incidence, Survival Rate, MESH: France, MESH: Survival Analysis, Female, France, MESH : Survival Analysis, MESH: Female, MESH : Registries
Abstract: International audience; Malignancies are rare young French adults but represent the third significant cause of death in the cohort of 15-24 years of age. The aim of this study was to investigate incidence and survival rates of French adolescents and young adults with cancer. All cases of cancer occuring over a 20-year period (1978-1997) in the cohort of patients aged 15 to 24, were obtained from nine population-based registries (10 % of the French population). Basal cell carcinomas of the skin were excluded. 1161 and 1884 cases were recorded in adolescents and young adults, respectively. Overall incidence rates (IR) were 161.4/10(6) in adolescents aged 15-19 years (M/F ratio = 1.3), and 252.6/10(6) in young adults aged 20-24 years (M/F ratio : 1.2). During the 1978-97 period, the IRs appeared stable over the years, +0.4 % [CI95 % = -2.3 ; +3.1] (p = 0.79) for adolescents and +1.7 % [CI95 % = -4.0 ; +7.3] (p = 0.57) for young adults. Five-year overall survival rates were 69.1 % [CI95 % = 66.4-71.8] for adolescents and 74.5 % [CI95 % = 72.3-76.7] for young adults. The 5-year survival rate for patients 15-24 years improved from 62.0 % (CI95 % = 57.5-66.5) in 1978-82 to 80.2 % (IC95 % = 77.7-82.8) in 1993-97. Noteworthy, results in adolescents and young adults are poor compared to the ones from their younger counterparts, especially in patients with acute lymphoblastic leukemia, non-Hodgkin lymphoma, Ewing's sarcoma, osteosarcoma, rhabdomyosarcoma, and astrocytoma. Further studies are warranted to elucidate whether these differences are due to intrinsic biological properties of the tumor or to differences in clinical practices in the two populations.
Published: 2007

43. Cancer adolescent pathway in France between 1988 and 1997

Author: Mélanie White-Koning, Nabil Maarouf, Laurence Brugières, Patricia Delafosse, Brigitte Trétarre, Danièle Sommelet, Anne-Valérie Guizard, Emmanuel Desandes, Angelina Marr, Brigitte Lacour, Christine Cotte, Michel Velten, Arlette Danzon, Centre Alexis Vautrin (CAV), Registre National des Tumeurs Solides de l'Enfant (RNTSE), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Cancéropôle du Grand Est, Registre des Cancers de l'Enfant de Lorraine, Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), FRANCIM, Réseau des registres français du cancer, Registre des cancers de la Manche, CHPC - Site Louis Pasteur, Centre Hospitalier Public du Cotentin (CHPC)-Centre Hospitalier Public du Cotentin (CHPC), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Département de Pédiatrie, Institut Gustave Roussy (IGR), Centre Alexis Vautrin ( CAV ), Registre National des Tumeurs Solides de l'Enfant ( RNTSE ), Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ) -Cancéropôle du Grand Est, Centre Hospitalier Régional Universitaire de Nancy ( CHRU Nancy ), registre des cancers de la Manche, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ) -Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ), and Institut Gustave Roussy ( IGR )
Subjects: Male, Pediatrics, MESH : Pediatrics, Adolescent cancer, Aftercare, MESH: Community Health Planning, Medical Oncology, MESH : Referral and Consultation, Health Services Accessibility, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, MESH: Aftercare, 0302 clinical medicine, MESH : Physician's Practice Patterns, MESH : Health Services Accessibility, MESH: Practice Guidelines as Topic, Neoplasms, hemic and lymphatic diseases, Outcome Assessment, Health Care, MESH: Cooperative Behavior, MESH : Female, MESH: Neoplasms, MESH: Specialties, Surgical, Cooperative Behavior, Practice Patterns, Physicians', 10. No inequality, Referral and Consultation, MESH: Medical Oncology, education.field_of_study, Clinical Trials as Topic, MESH: Health Services Accessibility, Oncology (nursing), Communication, General Medicine, MESH : Cooperative Behavior, MESH : Survival Rate, 3. Good health, Survival Rate, MESH : Practice Guidelines as Topic, 030220 oncology & carcinogenesis, Practice Guidelines as Topic, MESH: Pediatrics, Female, MESH: Communication, France, Health Services Research, MESH : Communication, Family Practice, MESH: Health Services Research, MESH : Health Services Needs and Demand, MESH: Health Services Needs and Demand, medicine.medical_specialty, Referral, Adolescent, MESH : Outcome Assessment (Health Care), MESH : Family Practice, MESH: Clinical Trials as Topic, MESH: Survival Rate, MESH : Male, Population, MESH : Health Services Research, [SDV.CAN]Life Sciences [q-bio]/Cancer, Community Health Planning, Specialties, Surgical, 03 medical and health sciences, MESH: Referral and Consultation, MESH : Medical Oncology, 030225 pediatrics, MESH : Adolescent, medicine, Cooperative group, Humans, education, MESH : France, MESH: Physician's Practice Patterns, MESH: Outcome Assessment (Health Care), MESH: Family Practice, MESH: Adolescent, Health Services Needs and Demand, MESH: Humans, MESH : Specialties, Surgical, business.industry, MESH : Humans, Cancer, medicine.disease, MESH : Neoplasms, MESH: Male, Clinical trial, MESH : Clinical Trials as Topic, MESH: France, MESH : Aftercare, Lymphoblastic leukaemia, business, Haematological malignancy, MESH : Community Health Planning, MESH: Female
Abstract: International audience; We report an adolescent cancer pathway from referral, through diagnosis and treatment, to follow-up in France. All cases of cancer among 15-19 years, diagnosed from 1988 to 1997, recorded by nine French population-based cancer registries (10% of French population) were included. The management of adolescent cancer by paediatricians was rare. An adolescents' pathway through cancer care can be summarized as first visit to general practitioner, referral to adult oncologist for haematological malignancy and medical or surgical specialists for solid tumours, treatment in adult unit, and follow-up by adult oncologist, adult medical or surgical specialist, or general practitioner. Only 9% of the 15-19 years are entered into a clinical trial (respectively 6% and 3% into adult and paediatric clinical trial). The inclusion rate changes according to the diagnosis, higher for acute lymphoblastic leukaemia (39%), non-Hodgkin's lymphomas (NHL) (27%), and acute non-lymphoblastic leukaemia (20%). Only 4% of adolescent cancers were managed on shared adult/paediatric departments, especially for soft-tissue sarcomas (14.9%), malignant bone tumours (13.4), central nervous system tumours (6.2%), and NHL (4.4%). Whatever the reasons for lack of participation in clinical trials, an ideal model requiring communication and cooperation between all adult and paediatric specialists involved in adolescent cancer treatment should reduce the large gap in access to cooperative groups.
Published: 2007

44. [Incidence and mortality of central nervous system tumors in France: trends over the period 1978-2000 and influence of registration practices on results]

Author: Ménégoz, F., Martin, E., Danzon, Arlette, Mathieu-Daudé, H., Guizard, A.-V., Macé-Lesec'H, J., Raverdy, N., Pasquier, B., Service de Dermatologie, Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Institut Fourier ( IF ), Centre National de la Recherche Scientifique ( CNRS ) -Université Grenoble Alpes ( UGA ), Viala, Pascale, Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Hôpital Saint-Jacques, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire [Besançon] (CHRU Besançon)-Université de Franche-Comté (UFC), Institut Fourier (IF), Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Hôpital Saint-Jacques, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Institut Fourier (IF ), and Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes [2016-2019] (UGA [2016-2019])
Subjects: Male, MESH: Survival Rate, MESH: Registries, MESH : Retrospective Studies, MESH : Sex Factors, MESH : Male, MESH : Aged, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Central Nervous System Neoplasms, MESH: Central Nervous System Neoplasms, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, Central Nervous System Neoplasms, Sex Factors, MESH: Sex Factors, [SDV.CAN] Life Sciences [q-bio]/Cancer, MESH: Risk Factors, Risk Factors, Humans, MESH : Female, MESH : Middle Aged, MESH: Incidence, Registries, MESH : France, Aged, Retrospective Studies, MESH: Aged, MESH: Humans, MESH: Middle Aged, Incidence, MESH : Humans, MESH: Retrospective Studies, Middle Aged, MESH : Survival Rate, MESH : Risk Factors, MESH: Male, MESH : Incidence, MESH: France, Survival Rate, Female, France, MESH: Female, MESH : Registries
Abstract: International audience; BACKGROUND: In France, cancer incidence figures are produced by cancer registries covering only 13.5% to 16% of the whole population of the country. Thus, to produce national figures, estimates have to be computed. Registration disparities between registries concerning tumors of the Central Nervous System (CNS) could have biased these estimates. METHODS: National estimates are based on modelling of the incidence/mortality ratio. The most recent estimations for year 2000 were calculated by the French Cancer Registry Network (FRANCIM) and the department of biostatistics of Lyon University Hospital. Since benign tumors are not recorded in some cancer registries, a new estimate of the incidence of CNS tumors was produced by estimating the number of benign tumors in these registries. RESULTS: In 2000 in France, the number of estimated cases of CNS tumors was 2697 in men and 2602 in women, with incidence rates (World standard) of 7.4 and 6.4 per 100,000 respectively. The incidence increased between 1978 and 2000, on an average by 2.25% per year in men and 3.01% per year in women. However, these estimates do not provide a correct picture of CNS incidence. First of all, pathological diagnoses are not performed in 3.5%-27.5% of the patients with CNS tumors registered in French registries. Second, figures for benign tumors (mainly meningiomas) were provided by only two of nine cancer registries. If benign tumors had been registered by all cancer registries, computed incidence would have increased by 12% for men and 26% for women. CONCLUSION: Incidence of CNS tumors is increasing in France, as in many other countries. To improve comparability with other countries, French cancer registries should also collect data on benign tumors. The discrepancies observed between registries in the proportion of patients without information on histology show differences in diagnostic practices and should be the starting point for a survey on this topic.
Published: 2006

45. Joint association of polymorphism of the FGFR4 gene and mutation TP53 gene with bladder cancer prognosis

Author: Victor E. Reuter, Carlos Cordon-Cardo, Arie S. Belldegrun, Zuo-Feng Zhang, Yonghui Yang, Guido Dalbagni, Ming-Lan Lu, Lin Cai, Wei Cao, Allan J. Pantuck, Jianyu Rao, Hervé Wallerand, Robert A. Figlin, Service d'urologie, andrologie et transplantation rénale, Université Bordeaux Segalen - Bordeaux 2-CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Department of Materials Science and Engineering, University of Florida [Gainesville], Département de pharmacochimie moléculaire ( DPM ), Université Joseph Fourier - Grenoble 1 ( UJF ) -Centre National de la Recherche Scientifique ( CNRS ), State Key Joint Laboratory of Environmental Simulation and Pollution Control, School of Environmental Science and Engineering, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Department of Materials Science and Engineering [Gainesville] (UF|MSE), University of Florida [Gainesville] (UF), Département de pharmacochimie moléculaire (DPM), Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université Joseph Fourier - Grenoble 1 (UJF), and Sun Yat-Sen University [Guangzhou] (SYSU)-Sun Yat-Sen University [Guangzhou] (SYSU)
Subjects: p53, Male, Cancer Research, Fibroblast Growth Factor, DNA Mutational Analysis, MESH: Genes, p53, MESH : Aged, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, single nucleotide polymorphism, Clinical Studies, Genotype, 2.1 Biological and endogenous factors, MESH : Female, MESH: DNA Mutational Analysis, Cancer, MESH: Aged, 0303 health sciences, MESH: Middle Aged, MESH : Prognosis, MESH: Polymorphism, Single Nucleotide, MESH : Polymorphism, Single Nucleotide, fibroblast growth factor receptor 4, TP53 mutation, Single Nucleotide, Middle Aged, Prognosis, MESH : Survival Rate, 3. Good health, MESH: Urinary Bladder Neoplasms, Survival Rate, Oncology, MESH : Urinary Bladder Neoplasms, 030220 oncology & carcinogenesis, MESH: Survival Analysis, Public Health and Health Services, bladder cancer, Female, MESH : Mutation, Type 4, Receptor, Urologic Diseases, MESH: Receptor, Fibroblast Growth Factor, Type 4, MESH: Mutation, Tumor suppressor gene, MESH: Survival Rate, MESH : Male, Oncology and Carcinogenesis, Single-nucleotide polymorphism, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : DNA Mutational Analysis, Biology, MESH : Receptor, Fibroblast Growth Factor, Type 4, Polymorphism, Single Nucleotide, MESH : Genes, p53, MESH: Prognosis, 03 medical and health sciences, Growth factor receptor, Clinical Research, Genetics, medicine, Humans, Receptor, Fibroblast Growth Factor, Type 4, MESH : Middle Aged, Oncology & Carcinogenesis, Polymorphism, Survival rate, Survival analysis, Aged, 030304 developmental biology, Bladder cancer, MESH: Humans, MESH : Humans, Fibroblast growth factor receptor 4, Genes, p53, medicine.disease, Survival Analysis, MESH: Male, Genes, Urinary Bladder Neoplasms, Mutation, Cancer research, MESH : Survival Analysis, MESH: Female
Abstract: International audience; The impact of the fibroblast growth factor receptor 4 (FGFR4) Gly388Arg polymorphism on bladder cancer is unknown. We found no clear correlations between the FGFR4 genotype and risk of bladder cancer or pathological parameters. Neither the polymorphism nor TP53 mutation status was an independent predictor of prognosis, but they might act jointly on the disease-specific survival of patients.
Published: 2006

46. Socioeconomic and geographic determinants of survival of patients with digestive cancer in France

Author: N. Maarouf, Michel Velten, Anne Marie Bouvier, Patricia Delafosse, Guy Launoy, Arlette Danzon, N. Bourdon-Raverdy, Brigitte Trétarre, Erik-André Sauleau, G. de Pouvourville, Olivier Dejardin, Pascale Grosclaude, S. Boutreux, L. Remontet, Florence Molinié, Hospices Civils de Lyon, Service de Biostatistique, Université de Lyon, Biostatistiques santé, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Cancer Registry of Isère, Département d'Ingénierie des Systèmes (ex SIS) (DIS), Institut de Recherches sur les lois Fondamentales de l'Univers (IRFU), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Registre des cancers du Bas-Rhin, CRLCC Paul Strauss, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Laboratoire Biostatistique-Santé ( LBS ), Université Claude Bernard Lyon 1 ( UCBL ), Université de Lyon-Université de Lyon-Hospices Civils de Lyon ( HCL ) -Centre National de la Recherche Scientifique ( CNRS ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Département d'Ingénierie des Systèmes (ex SIS) ( DIS ), Institut de Recherches sur les lois Fondamentales de l'Univers ( IRFU ), and Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay-Commissariat à l'énergie atomique et aux énergies alternatives ( CEA ) -Université Paris-Saclay
Subjects: Male, Cancer Research, MESH: Registries, Epidemiology, Colorectal cancer, MESH : Aged, Digestive System Neoplasms, deprivation, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, MESH : Socioeconomic Factors, MESH : Female, Registries, 030212 general & internal medicine, Digestive cancer, MESH: Aged, MESH : Prognosis, MESH: Middle Aged, Middle Aged, Prognosis, MESH : Survival Rate, 3. Good health, Survival Rate, Oncology, 030220 oncology & carcinogenesis, Female, France, digestive cancer, Small intestine cancer, medicine.medical_specialty, MESH: Socioeconomic Factors, MESH: Survival Rate, MESH : Male, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH: Patient Care, MESH: Prognosis, 03 medical and health sciences, Internal medicine, medicine, Humans, MESH : Middle Aged, distance, MESH : France, Survival rate, Socioeconomic status, Aged, MESH: Humans, business.industry, Proportional hazards model, MESH: Digestive System Neoplasms, MESH : Humans, Cancer, MESH : Patient Care, medicine.disease, MESH: Male, Surgery, MESH: France, Socioeconomic Factors, Relative risk, road distance, Patient Care, MESH : Digestive System Neoplasms, business, MESH: Female, multilevel Cox model, MESH : Registries
Abstract: International audience; Using a multilevel Cox model, the association between socioeconomic and geographical aggregate variables and survival was investigated in 81 268 patients with digestive tract cancer diagnosed in the years 1980-1997 and registered in 12 registries in the French Network of Cancer Registries. This association differed according to cancer site: it was clear for colon (relative risk (RR)=1.10 (1.04-1.16), 1.10 (1.04-1.16) and 1.14 (1.05-1.23), respectively, for distances to nearest reference cancer care centre between 10 and 30, 30 and 50 and more than 90 km, in comparison with distance of less than 10 km; P-trend=0.003) and rectal cancer (RR=1.09 (1.03-1.15), RR=1.08 (1.02-1.14) and RR=1.12 (1.05-1.19), respectively, for distances between 10 and 30 km, 30 and 50 km and 50 and 70 km, P-trend=0.024) (n=28 010 and n=18 080, respectively) but was not significant for gall bladder and biliary tract cancer (n=2893) or small intestine cancer (n=1038). Even though the influence of socioeconomic status on prognosis is modest compared to clinical prognostic factors such as histology or stage at diagnosis, socioeconomic deprivation and distance to nearest cancer centre need to be considered as potential survival predictors in digestive tract cancer.
Published: 2006

47. Long-duration, weekly treatment with gemcitabine plus vinorelbine for non-small cell lung cancer: a multicenter phase II study

Author: Jean-Luc Breton, C. Germa, Denis Braun, E. Quoix, Virginie Westeel, P. Jacoulet, A. Depierre, Didier Debieuvre, L. Kayitalire, B. Milleron, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Information et Chaos Quantiques (LPT), Laboratoire de Physique Théorique (LPT), Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Laboratoire de Physique Théorique - IRSAMC ( LPT ), Université Paul Sabatier - Toulouse 3 ( UPS ) -Centre National de la Recherche Scientifique ( CNRS ) -Université Paul Sabatier - Toulouse 3 ( UPS ) -Centre National de la Recherche Scientifique ( CNRS ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (UR 3181) (CEF2P / CARCINO), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), and Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)
Subjects: Male, Cancer Research, Lung Neoplasms, MESH : Antineoplastic Combined Chemotherapy Protocols, MESH : Aged, Phases of clinical research, Deoxycytidine, Gastroenterology, [ SDV.CAN ] Life Sciences [q-bio]/Cancer, 0302 clinical medicine, Carcinoma, Non-Small-Cell Lung, Antineoplastic Combined Chemotherapy Protocols, MESH : Female, MESH: Treatment Outcome, MESH: Aged, 0303 health sciences, MESH: Middle Aged, Respiratory disease, Vinorelbine, Middle Aged, MESH : Adult, MESH : Survival Rate, 3. Good health, Survival Rate, MESH: Antineoplastic Combined Chemotherapy Protocols, Treatment Outcome, Oncology, 030220 oncology & carcinogenesis, Disease Progression, Female, MESH: Disease Progression, medicine.drug, Adult, Pulmonary and Respiratory Medicine, medicine.medical_specialty, MESH: Survival Rate, MESH : Male, MESH: Vinblastine, [SDV.CAN]Life Sciences [q-bio]/Cancer, MESH : Treatment Outcome, Neutropenia, Vinblastine, MESH : Vinblastine, 03 medical and health sciences, MESH : Deoxycytidine, Internal medicine, medicine, Humans, MESH : Middle Aged, MESH : Lung Neoplasms, Lung cancer, Aged, 030304 developmental biology, MESH : Carcinoma, Non-Small-Cell Lung, MESH: Humans, business.industry, MESH : Humans, MESH: Deoxycytidine, MESH: Adult, MESH : Disease Progression, medicine.disease, Gemcitabine, MESH: Male, Surgery, MESH: Lung Neoplasms, Regimen, business, MESH: Female, Febrile neutropenia, MESH: Carcinoma, Non-Small-Cell Lung
Abstract: International audience; In this phase II study, gemcitabine and vinorelbine were combined at suboptimal doses for weekly administration in advanced non-small cell lung cancer (NSCLC). The primary objectives were to determine objective response rate (ORR) and time to progression (TTP). Secondary endpoints were safety and overall survival. Chemonaive patients with histologically or cytologically confirmed stage IIIB or IV NSCLC received vinorelbine (25 mg/m2) immediately followed by gemcitabine (800 mg/m2) once each week (on day 1) for 6 months without rest. From May 1998 to May 1999, 40 patients were enrolled (85% males; 70% stage IV) with a median age of 65.5. A total of 478 doses were administered, with a median of 9 per patient (range 2-72). The ORR was 27.5% (95% CI, 15.1-44.1%). The median TTP was 3.5 months (95% CI, 2.9-4.4 months). At a median follow-up of 6.5 months, the median survival was 11.6 months, and survival rates at 1 and 2 year(s) were 47.5% and 15.8%, respectively. The most common grade 3/4 hematologic toxicity was neutropenia, in 70% of patients, with febrile neutropenia in 28%. The most common grade 3/4 non-hematologic toxicity was transaminase elevation, in 22.5% of patients, which was transient and reversible. The other most prominent toxicities were, unexpectedly, pulmonary and cardiac toxicities. Based on these results, weekly, long-term administration of gemcitabine-vinorelbine appears to be an active regimen in NSCLC that warrants further investigation.
Published: 2006

48. Determinants of mortality for adults with cystic fibrosis admitted in Intensive Care Unit: a multicenter study

Author: Jean-Paul Mira, Dany Jamal, Joelle Texereau, Daniel Dusser, Pierre-Régis Burgel, Antoine Rabbat, Gerald Choukroun, Philippe Loirat, Jean-Luc Diehl, Dominique Hubert, Alexandre Duguet, Joël Coste, Antoine Parrot, Service de physiologie et explorations fonctionelles [CHU Cochin], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Cochin (UMR_S567 / UMR 8104), Université Paris Descartes - Paris 5 (UPD5)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Service de réanimation médicale polyvalente [CHU Cochin], Hôpital Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de pneumologie [CHU Cochin], Service de réanimation médicale [CHU HEGP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Service de Pneumologie – Réanimation Médicale, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôtel-Dieu, Service de Réanimation Médicale, Hôpital Foch [Suresnes], Laboratoire d'Acoustique de l'Université du Mans (LAUM), Centre National de la Recherche Scientifique (CNRS)-Le Mans Université (UM), Service d'anesthésie et réanimation [CHU Tenon], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Service de Pneumologie – Réanimation Médicale [CHU Pitié-Salpêtrière], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Service d'informatique médicale [CHU Cochin], Le Mans Université (UM)-Centre National de la Recherche Scientifique (CNRS), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Autard, Delphine, CHU Cochin [AP-HP]-Assistance publique - Hôpitaux de Paris (AP-HP), Institut Cochin ( UMR_S567 / UMR 8104 ), Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Cochin [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôtel-Dieu, Laboratoire d'acoustique de l'université du Mans ( LAUM ), Le Mans Université ( UM ) -Centre National de la Recherche Scientifique ( CNRS ), Service d'anesthésie et réanimation, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Tenon [APHP], and Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP]
Subjects: Male, Exacerbation, Cystic Fibrosis, MESH: Risk Assessment, Cystic fibrosis, MESH : Intensive Care, [SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, law.invention, MESH: Proportional Hazards Models, 0302 clinical medicine, law, Risk Factors, MESH: Risk Factors, Outcome Assessment, Health Care, MESH : Female, 030212 general & internal medicine, MESH : Risk Assessment, MESH: Respiration, Artificial, MESH : Prognosis, MESH : Adult, MESH : Survival Rate, Prognosis, Intensive care unit, MESH : Risk Factors, 3. Good health, Survival Rate, Intensive Care Units, medicine.anatomical_structure, MESH: Survival Analysis, Female, France, MESH : Intensive Care Units, Pulmonary and Respiratory Medicine, Adult, medicine.medical_specialty, MESH : Outcome Assessment (Health Care), Critical Care, MESH: Cystic Fibrosis, MESH: Survival Rate, MESH : Male, Risk Assessment, MESH: Prognosis, 03 medical and health sciences, Intensive care, MESH : Cystic Fibrosis, medicine, Humans, MESH: Intensive Care, MESH : Respiration, Artificial, Intensive care medicine, MESH : France, Survival rate, MESH: Outcome Assessment (Health Care), Survival analysis, Proportional Hazards Models, lcsh:RC705-779, Lung, MESH: Humans, Proportional hazards model, business.industry, Research, MESH : Humans, MESH: Adult, lcsh:Diseases of the respiratory system, medicine.disease, MESH : Proportional Hazards Models, Respiration, Artificial, Survival Analysis, MESH: Male, MESH: France, 030228 respiratory system, Emergency medicine, [SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract, MESH: Intensive Care Units, MESH : Survival Analysis, business, MESH: Female, [ SDV.MHEP.PSR ] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Abstract: Background Intensive care unit (ICU) admission of adults with cystic fibrosis (CF) is controversial because of poor outcome. This appraisal needs re-evaluation following recent changes in both CF management and ICU daily practice. Objectives were to determine long-term outcome of adults with CF admitted in ICU and to identify prognostic factors. Methods Retrospective multicenter study of 60 ICU hospitalizations for 42 adult CF patients admitted between 2000 and 2003. Reason for ICU admission, ventilatory support provided and one-year survival were recorded. Multiple logistic analysis was used to determine predictors of mortality. Results Prior to ICU admission, all patients (mean age 28.1 ± 8 yr) had a severe lung disease (mean FEV1 28 ± 12% predicted; mean PaCO2 47 ± 9 mmHg). Main reason for ICU hospitalization was pulmonary infective exacerbation (40/60). At admission, noninvasive ventilation was used in 57% of cases and was successful in 67% of patients. Endotracheal intubation was implemented in 19 episodes. Overall ICU mortality rate was 14%. One year after ICU discharge, 10 of the 28 survivors have been lung transplanted. Among recognized markers of CF disease severity, only the annual FEV1 loss was associated with a poor outcome (HR = 1.47 [1.18–1.85], p = 0.001). SAPSII (HR = 1.08 [1.03–1.12], p < 0.001) and endotracheal intubation (HR = 16.60 [4.35–63.34], p < 0.001) were identified as strong independent predictors of mortality. Conclusion Despite advanced lung disease, adult patients with CF admitted in ICU have high survival rate. Endotracheal intubation is associated with a poor prognosis and should be used as the last alternative. Although efforts have to be made in selecting patients with CF likely to benefit from ICU resources, ICU admission of these patients should be considered.
Published: 2006

49. CDX2 expression in cutaneous metastatic carcinomas and extramammary Paget's disease

Author: Lora, V., Jean Kanitakis, Clinique Dermatologique, Hospices Civils de Lyon (HCL) - Hôpital Edouard Herriot [CHU - HCL], Hospices Civils de Lyon (HCL), and Kanitakis, Jean
Subjects: MESH : Prognosis, MESH : Male, MESH : Skin Neoplasms, MESH : Humans, MESH : Follow-Up Studies, [SDV.MHEP.DERM] Life Sciences [q-bio]/Human health and pathology/Dermatology, MESH : Survival Rate, digestive system diseases, MESH : Colonic Neoplasms, MESH : Paget Disease Extramammary, MESH : Immunoenzyme Techniques, MESH : Tumor Markers, Biological, embryonic structures, MESH : Female, MESH : Neoplasm Staging, MESH : Homeodomain Proteins
Abstract: International audience; BACKGROUND: CDX2 is a gene involved in the regulation of intestinal cell proliferation/differentiation. It is considered specific for enterocytes and has been used for the diagnosis of primary and metastatic colon adenocarcinoma. The aim of this study was to assess the usefulness of CDX2 in the diagnosis of cutaneous metastatic tumors and extramammary Paget's disease. MATERIALS AND METHODS: The immunohistochemical expression of CDX2 was studied in 68 cutaneous metastatic tumors of various origins and 14 specimens of extramammary Paget's disease. RESULTS: CDX2 expression was found in 3/6 metastases of colon adenocarcinoma, 1/1 metastasis of urothelial carcinoma and 1/2 extramammary Paget's disease. CONCLUSION: CDX2 appears to be specific for cutaneous metastases from intestinal and urothelial carcinomas and is a useful diagnostic marker of these tumors. However, its sensitivity is modest, and we advocate its use in conjunction with additional immunohistochemical markers. CDX2 seems useful for the diagnosis of extramammary Paget's disease associated with an underlying colorectal tumor.

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Journal

Database

Publisher

49 results on '"MESH : Survival Rate"'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources